var title_f3_19_3376="Full thickness burn";
var content_f3_19_3376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Full-thickness burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Burn areas that are waxy white or leathery gray and insensate characterize full-thickness burns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Morgan, MD and William F Miser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3376=[""].join("\n");
var outline_f3_19_3376=null;
var title_f3_19_3377="Ringworm (including athlete's foot and jock itch)";
var content_f3_19_3377=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Ringworm (including athlete's foot and jock itch) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/19/3377/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3377/contributors\" id=\"au5345\">",
"       Adam O Goldstein, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3377/contributors\" id=\"au5343\">",
"       Beth G Goldstein, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/19/3377/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3377/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3377/contributors\" id=\"se4893\">",
"       Moise L Levy, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/19/3377/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3377/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3377/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/19/3377?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      RINGWORM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Despite its name, ringworm is not caused by a worm. Ringworm is actually an infection caused by a fungus. It is called ringworm because it can cause a ring-shaped, red, itchy rash on the skin. Ringworm is also called tinea.",
"    </p>",
"    <p>",
"     There are four different types of ringworm infections, which are named from the body-part that is affected:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Tinea capitis affects the top of the head, or scalp, and is found mostly in children",
"      </li>",
"      <li>",
"       Tinea pedis affects the feet, and is also called \"athlete's foot\"",
"      </li>",
"      <li>",
"       Tinea cruris affects the groin, and is also called \"jock itch\"",
"      </li>",
"      <li>",
"       Tinea corporis is the catch-all term for tinea infections on other body surfaces",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You can catch ringworm from someone else who is infected, or even from an infected dog or cat. You can also pick up it from objects, such as a shower stall, locker room floor, or pool area that has the fungus. Plus, you can spread ringworm from one body part (such as your feet) to another (such as your groin).",
"    </p>",
"    <p>",
"     If you have ringworm, your healthcare provider may be able diagnose it just by looking at your rash. In some cases,",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     will take some scrapings of the rash and look at it under a microscope to check for the fungus.",
"    </p>",
"    <p>",
"     This article will discuss the symptoms and treatment of each type of ringworm infection. More detailed information about tinea is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"      \"Dermatophyte (tinea) infections\"",
"     </a>",
"     .) Fungal nail infections are also discussed separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link\">",
"      \"Onychomycosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SCALP INFECTION (TINEA CAPITIS)",
"     </span>",
"    </p>",
"    <p>",
"     Tinea capitis usually causes a scaly, red rash that can lead to bald patches on the scalp (",
"     <a class=\"graphic graphic_picture graphicRef77493 \" href=\"UTD.htm?31/3/31797\">",
"      picture 1",
"     </a>",
"     ). It usually affects children and only rarely affects adults.",
"    </p>",
"    <p>",
"     Scalp infections are treated with prescription antifungal medicines that you take by mouth. Topical treatments (lotions or creams) for tinea infections do not work on scalp infections. Treatment usually requires taking the medication once or twice per day for 2 to 12 weeks depending on the type of medication given and how well the infection responds to treatment.",
"    </p>",
"    <p>",
"     To prevent tinea capitis from recurring, it's important to get rid of any combs, barrettes, or other hair products that could be harboring the fungus. Family members should also be checked and treated, if necessary.",
"    </p>",
"    <p>",
"     You can carry and spread the fungus but show no signs of infection; this person is called a carrier. In cases where the family pet is suspected to be the source of the infection, it's also important to have the animal treated.",
"    </p>",
"    <p>",
"     If your child is being treated for tinea capitis with oral antifungal drugs,",
"     <span class=\"nowrap\">",
"      s/he",
"     </span>",
"     can still go to school. There is no need to shave your child's head or cut their hair.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ATHLETE'S FOOT (TINEA PEDIS)",
"     </span>",
"    </p>",
"    <p>",
"     Tinea pedis causes the skin on the feet &mdash; often between the toes &mdash; to become itchy, red, cracked, tender, and scaly (",
"     <a class=\"graphic graphic_picture graphicRef55602 graphicRef63389 \" href=\"UTD.htm?38/29/39380\">",
"      picture 2A-B",
"     </a>",
"     ). Sometimes it also causes blisters to form. People who have tinea pedis often also have the infection on their hands, under their nails, or on their groin.",
"    </p>",
"    <p>",
"     Unlike tinea capitis, tinea pedis responds to most topical antifungal treatments, many of which are available without a prescription. The",
"     <span class=\"nowrap\">",
"      cream/gel/lotion/powder",
"     </span>",
"     is usually applied once or twice daily for four weeks (",
"     <a class=\"graphic graphic_table graphicRef82658 \" href=\"UTD.htm?19/47/20219\">",
"      table 1",
"     </a>",
"     ). In severe or long-lasting cases, your healthcare provider may suggest an oral antifungal drug (which is available only by prescription).",
"    </p>",
"    <p>",
"     To improve comfort and reduce the chances of repeat infection, it is a good idea to use antifungal foot powders, both on the feet and in the shoes, and to wear open shoes, at least while the feet heal.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      JOCK ITCH (TINEA CRURIS)",
"     </span>",
"    </p>",
"    <p>",
"     Tinea cruris usually starts by causing a red, itchy rash in the groin, the crease where the leg meets the trunk. From there, it can spread onto the thighs and toward the buttocks or anus. It is more common in men than in women, and it often surfaces during warm or hot weather, after a bout of heavy sweating. The most common source of this infection is the person's own tinea pedis (athlete's foot).",
"    </p>",
"    <p>",
"     Most cases of tinea cruris can be successfully treated with an antifungal",
"     <span class=\"nowrap\">",
"      cream/lotion/gel,",
"     </span>",
"     some of which are available without a prescription. The treatment is usually applied once or twice per day for three to four weeks (",
"     <a class=\"graphic graphic_table graphicRef82658 \" href=\"UTD.htm?19/47/20219\">",
"      table 1",
"     </a>",
"     ). It's essential, though, to treat tinea pedis (athlete's foot) at the same time; otherwise the groin infection will likely recur. During treatment, avoid tight-fitting clothes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      BODY INFECTION (TINEA CORPORIS)",
"     </span>",
"    </p>",
"    <p>",
"     Tinea corporis is an infection that appears on a part of the body other than those listed above. Tinea corporis often develops when a tinea infection is transferred from another part of the body. It can also happen to parents who are caring for children with tinea capitis. It appears as a circular or oval scaly area. The outer edge is usually red and slightly raised while the center is flat and skin colored.",
"    </p>",
"    <p>",
"     Tinea corporis usually responds to treatment with an antifungal",
"     <span class=\"nowrap\">",
"      cream/gel/lotion",
"     </span>",
"     once or twice per day for one to two weeks (",
"     <a class=\"graphic graphic_table graphicRef82658 \" href=\"UTD.htm?19/47/20219\">",
"      table 1",
"     </a>",
"     ). Athletes who have tinea corporis and who have close body contact (eg, wrestlers) may not be allowed to compete until the infection has cleared.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      PREVENTING RINGWORM",
"     </span>",
"    </p>",
"    <p>",
"     To prevent ringworm and other skin infections:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Do not share clothing, sports equipment, or towels with other people.",
"      </li>",
"      <li>",
"       When at the gym, local pool, or other public areas (including the shower), always wear slippers or sandals.",
"      </li>",
"      <li>",
"       Wash thoroughly with soap and shampoo after any sport involving skin-to-skin contact.",
"      </li>",
"      <li>",
"       Avoid tight-fitting clothing. Change your socks and underwear at least once a day.",
"      </li>",
"      <li>",
"       Keep your skin clean and dry. Always dry yourself completely after bathing.",
"      </li>",
"      <li>",
"       If you have athlete's foot, put your socks on before your underwear so that the infection does not spread to other parts of your body.",
"      </li>",
"      <li>",
"       Take your pet to the vet if it has patches of missing hair or a rash. That could be a sign of a tinea infection.",
"      </li>",
"      <li>",
"       If you or someone in your family has symptoms of ringworm, make sure",
"       <span class=\"nowrap\">",
"        s/he",
"       </span>",
"       is treated right away. Otherwise, the infection may spread.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H431642\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H431649\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/0/33793?source=see_link\">",
"      Patient information: Ringworm, athlete&rsquo;s foot, and jock itch (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H431673\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5258?source=see_link\">",
"      Onychomycosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/tineainfections.html\">",
"      www.nlm.nih.gov/medlineplus/tineainfections.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/nczved/dfbmd/disease_listing/dermatophytes_gi.html\">",
"      www.cdc.gov/nczved/dfbmd/disease_listing/dermatophytes_gi.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       KidsHealth",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/teen/infections/fungal/ringworm.html\">",
"      file://kidshealth.org/teen/infections/fungal/ringworm.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?3/19/3377/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/19/3377?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3377/abstract/1\">",
"      Fuller LC, Child FJ, Midgley G, Higgins EM. Diagnosis and management of scalp ringworm. BMJ 2003; 326:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3377/abstract/2\">",
"      Gonz&aacute;lez U, Seaton T, Bergus G, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev 2007; :CD004685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3377/abstract/3\">",
"      Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007; :CD001434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3377/abstract/4\">",
"      Bell-Syer SE, Hart R, Crawford F, et al. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2002; :CD003584.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_19_3377=[""].join("\n");
var outline_f3_19_3377=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           RINGWORM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SCALP INFECTION (TINEA CAPITIS)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ATHLETE'S FOOT (TINEA PEDIS)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           JOCK ITCH (TINEA CRURIS)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           BODY INFECTION (TINEA CORPORIS)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           PREVENTING RINGWORM",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/3/31797\" title=\"picture 1\">",
"           Tinea capitis PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/23/26992\" title=\"picture 2A\">",
"           Chronic tinea pedis PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/12/37071\" title=\"picture 2B\">",
"           Athletes foot PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?19/47/20219\" title=\"table 1\">",
"           Antifungal treatments PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_19_3378="Pedunculated gastric carcinoid";
var content_f3_19_3378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view demonstrates a solitary, pedunculated gastric carcinoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of Tumor Pathology (electronic fascicle), Third series, Fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3378=[""].join("\n");
var outline_f3_19_3378=null;
var title_f3_19_3379="Proptosis and chemosis";
var content_f3_19_3379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proptosis and chemosis in a direct, high-flow, right carotid cavernous fistula following trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Norman J Schatz, MD. Reproduced from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3379=[""].join("\n");
var outline_f3_19_3379=null;
var title_f3_19_3380="Gentian violet: Patient drug information";
var content_f3_19_3380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gentian violet: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=see_link\">",
"     see \"Gentian violet: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/61/26578?source=see_link\">",
"     see \"Gentian violet: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702198",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gentian violet or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain clothing or fabric.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705458",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Mouth:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694436",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected part with a cotton swab.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected part with a cotton swab and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11956 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3380=[""].join("\n");
var outline_f3_19_3380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011735\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011734\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011739\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011740\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011742\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011737\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011738\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011743\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011744\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=related_link\">",
"      Gentian violet: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/61/26578?source=related_link\">",
"      Gentian violet: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_19_3381="Inverse psoriasis groin";
var content_f3_19_3381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverse psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques involve the inguinal area in this patient with inverse psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3381=[""].join("\n");
var outline_f3_19_3381=null;
var title_f3_19_3382="Insulin lispro protamine and insulin lispro: Pediatric drug information";
var content_f3_19_3382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin lispro protamine and insulin lispro: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12551?source=see_link\">",
"    see \"Insulin lispro protamine and insulin lispro: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/37/9813?source=see_link\">",
"    see \"Insulin lispro protamine and insulin lispro: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2176667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumaLOG&reg; Mix 50/50&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 50/50&trade; KwikPen&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 75/25&trade;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; Mix 75/25&trade; KwikPen&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog&reg; Mix 25",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2984427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Combination",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2984438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12551?source=see_link\">",
"      see \"Insulin lispro protamine and insulin lispro: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lispro protamine is an intermediate-acting insulin and lispro is a rapid-acting insulin administered by SubQ injection. Insulin lispro protamine and insulin lispro combination products are approximately equipotent to insulin NPH and insulin regular combination products with a similar duration of activity but a more rapid onset. With combination insulin products, the proportion of rapid-acting to long-acting insulin is fixed; basal vs prandial dose adjustments cannot be made. Fixed ratio insulins (such as insulin lispro protamine and insulin lispro combination) are typically administered as 2 daily doses with each dose intended to cover two meals and a snack. Because of variability in the peak effect and individual patient variability in activities, meals, etc, it may be more difficult to achieve complete glycemic control using fixed combinations of insulins; frequent monitoring and close medical supervision may be necessary. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     . Insulin lispro protamine and insulin lispro combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Insulin lispro protamine and insulin lispro combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 50/50&trade;: Insulin lispro protamine suspension 50% [intermediate acting] and insulin lispro solution 50% [rapid acting]: 100 units/mL  (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 50/50&trade; KwikPen&trade;: Insulin lispro protamine suspension 50% [intermediate acting] and insulin lispro solution 50% [rapid acting]: 100 units/mL (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 75/25&trade;: Insulin lispro protamine suspension 75% [intermediate acting] and insulin lispro solution 25% [rapid acting]: 100 units/mL  (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumaLOG&reg; Mix 75/25&trade; KwikPen&trade;: Insulin lispro protamine suspension 75% [intermediate acting] and insulin lispro solution 25% [rapid acting]: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2345303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2984439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: SubQ: Gently roll vial or pen in the palms of the hands to resuspend before use; administer into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated. Cold injections should be avoided. Administer within 15 minutes before a meal (breakfast and supper). Do not mix or dilute with other insulins.",
"     <b>",
"      Not for I.V. administration",
"     </b>",
"     or use in an insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2138119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin NPH, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2984435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened container or pen in refrigerator; do not freeze; protect from light. If refrigeration is not possible, vial (in use) may be stored at room temperature for up to 28 days. The pen (in use) should",
"     <b>",
"      not",
"     </b>",
"     be refrigerated; store below 30&deg;C (86&deg;F) away from direct heat or light; discard after 10 days. Do not mix or dilute with other insulins.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2984428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM); type 2 diabetes mellitus (noninsulin dependent, NIDDM) to control hyperglycemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2137984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumaLOG&reg; Mix 50/50&trade; may be confused with HumaLOG&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumaLOG&reg; Mix 75/25&trade; may be confused with HumuLIN&reg; 70/30, NovoLIN&reg; 70/30, and NovoLOG&reg; Mix 70/30",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2345307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2984430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin lispro, insulin lispro protamine, or any component; hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2984431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating. Not for I.V. infusion or use in insulin infusion pumps",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8103651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2345309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2138108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2138109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Insulin lispro has not been shown to cross the placenta at standard clinical doses. Although congenital anomalies have been noted in case reports, when compared to regular insulin, insulin lispro has not been found to increase the risk of adverse events to the fetus in larger studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. The use of insulin lispro has been shown to be as effective as regular insulin to treat diabetes in pregnancy and may have advantages over regular insulin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2984443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2984444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial** : Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2984436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin lispro protamine and insulin lispro is a combination product with a rapid onset and a duration of action which is similar to intermediate-acting insulin products.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 0.25-0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 18-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2984437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Time to peak serum concentration: 1 hour (median; range: 0.5-4 hours)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2984445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/37/9813?source=see_link\">",
"      see \"Insulin lispro protamine and insulin lispro: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12780 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-BD52B341D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3382=[""].join("\n");
var outline_f3_19_3382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2176667\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186198\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984427\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984438\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104239\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345303\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984439\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138119\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984435\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984428\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137984\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345307\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984430\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984441\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984431\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103651\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2345309\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984434\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138108\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138109\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984443\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984444\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984436\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984442\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984437\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984445\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455358\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12551?source=related_link\">",
"      Insulin lispro protamine and insulin lispro: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/37/9813?source=related_link\">",
"      Insulin lispro protamine and insulin lispro: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_19_3383="Ultrapure dialysate";
var content_f3_19_3383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ultrapure dialysate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3383/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3383/contributors\">",
"     Richard A Ward, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3383/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3383/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3383/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3383/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/19/3383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis patients are at risk of injury from chemical and microbiological contaminants in the dialysate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=see_link\">",
"     \"Contaminants in water used for hemodialysis\"",
"    </a>",
"    .) To avoid injury from these contaminants, the water and concentrates used to produce dialysate, as well as the dialysate itself, are required to meet well-established quality standards [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Compliance with these standards has largely eliminated acute adverse events resulting from dialysate contamination.",
"   </p>",
"   <p>",
"    Long-term morbidity from exposure to chemical contaminants in the dialysate is also rare, providing the water and concentrates used to prepare dialysate are of the requisite quality. However, preventing long-term morbidity from exposure to microbiological contaminants is more difficult.",
"   </p>",
"   <p>",
"    Because the chlorine compounds used to suppress bacterial growth in the potable water supply are removed when the water is treated for hemodialysis, it is almost impossible to completely prevent bacterial proliferation in the treated water and the dialysate. As a result, even though conventional dialysate meets the required quality standards, it usually contains some low level of microbiological contamination, including fragments of endotoxin, peptidoglycans, and fragments of bacterial DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. These contaminants, sometimes collectively referred to as \"cytokine-inducing substances,\" cross both low-flux and high-flux hemodialysis membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/5,7\">",
"     5,7",
"    </a>",
"    ] and stimulate cytokine production by inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma levels of C-reactive protein (CRP) and interleukin-6 (IL-6) are elevated in many hemodialysis patients, suggesting a state of chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This inflammatory state may be an important contributor to the long-term morbidity associated with hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/11\">",
"     11",
"    </a>",
"    ]. While inflammation appears to be a consequence of chronic kidney disease, per se [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], aspects of the hemodialysis procedure, including low levels of microbiological contaminants in the dialysate, may also act as inflammatory stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For this reason, the use of dialysate of much higher microbiological purity than is required has been recommended for routine hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. This \"ultrapure\" dialysate is commonly defined as having a bacterial count less than 100",
"    <span class=\"nowrap\">",
"     CFU/L",
"    </span>",
"    and an endotoxin content less than 0.03",
"    <span class=\"nowrap\">",
"     EU/mL",
"    </span>",
"    measured by the Limulus amebocyte lysate assay [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/16\">",
"     16",
"    </a>",
"    ]. Use of ultrapure dialysate is required for on-line hemodiafiltration and hemofiltration, where dialysate is used to prepare the substitution solution [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30330?source=see_link\">",
"     \"Alternative renal replacement therapies in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of ultrapure dialysate in patients undergoing routine hemodialysis is presented herein. A general overview of maintaining water quality for hemodialysis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=see_link\">",
"     \"Maintaining water quality for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSOCIATION BETWEEN LOW LEVELS OF DIALYSATE CONTAMINATION AND INFLAMMATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients treated with dialysate that meets current requirements for microbiological quality have at least a low level of chronic inflammation as evidenced by increased plasma levels of CRP and IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Changing from standard dialysate to ultrapure dialysate results in a significant reduction in the plasma concentration of both CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18-26\">",
"     18-26",
"    </a>",
"    ] and IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18,19,24\">",
"     18,19,24",
"    </a>",
"    ], consistent with a role for microbiological contaminants from the dialysate in the inflammation associated with chronic hemodialysis.",
"   </p>",
"   <p>",
"    Not all studies report a reduction in inflammatory markers after the introduction of ultrapure dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. There are clearly many stimuli to inflammation in hemodialysis patients, such as the presence of synthetic grafts for blood access and the practice of dialyzer reuse. Thus, a failure to find a reduction in the level of inflammatory markers with ultrapure dialysate may reflect the presence of multiple inflammatory stimuli.",
"   </p>",
"   <p>",
"    Alternatively, the possibility exists that the decrease in plasma levels of CRP and IL-6 observed following the change to ultrapure dialysate represents regression to the mean, given the largely observational nature of the studies in this area and the well-documented variability in plasma levels of CRP and IL-6 over time, even in apparently stable patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, there are insufficient data to definitively show that ultrapure dialysate reduces inflammation in hemodialysis patients, although the preponderance of data supports that conclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation is thought to contribute to many aspects of the comorbidity associated with long-term hemodialysis. Based on the reduction in inflammation reported to occur after the introduction of ultrapure dialysate, a number of investigators have examined the impact of ultrapure dialysate on patient outcomes believed to be associated with inflammation.",
"   </p>",
"   <p>",
"    While not meeting the strongest standards of evidence, the overall finding of these generally small, mostly observational studies is that ultrapure dialysate mitigates some of the long-term morbidity associated with hemodialysis. None of these benefits have been demonstrated in large multi-center randomized clinical trials and, to date, insufficient information has been reported to allow a formal meta-analysis.",
"   </p>",
"   <p>",
"    The incremental cost of using available technology to provide ultrapure dialysate is small compared to the cost and logistical problems of performing a large randomized clinical trial. Moreover, there is no evidence that use of ultrapure dialysate has any detrimental effect on patient outcomes. For these reasons, it seems unlikely that large-scale randomized clinical trials of ultrapure dialysate will be performed.",
"   </p>",
"   <p>",
"    The most common findings are that the use of ultrapure dialysate is associated with improvements in anemia correction, beta2-microglobulin accumulation, and nutritional status. The findings of these studies are summarized in the following paragraphs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anemia correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the more commonly reported benefits of ultrapure dialysate is improved utilization of erythropoietin-stimulating agents (ESA), whether a decrease in the dose needed to achieve a target hematocrit or hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18,20,22,25\">",
"     18,20,22,25",
"    </a>",
"    ] or an increase in hematocrit or hemoglobin achieved with no change in dose [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/21,23,26\">",
"     21,23,26",
"    </a>",
"    ]. Reductions of 16 to 34 percent in the ESA dose required to achieve the target hematocrit or hemoglobin were reported in two observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/20,25\">",
"     20,25",
"    </a>",
"    ] and two randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18,22\">",
"     18,22",
"    </a>",
"    ] that followed 25 to 100 patients for 6 to 12 months, mostly in single centers. In three observational studies where the ESA dose did not change, hemoglobin levels were reported to increase by about 10 percent over 6 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/21,23,26\">",
"     21,23,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies have shown an improvement in ESA utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The reasons why these two studies did not find better ESA utilization are not clear. It may be significant that the introduction of ultrapure dialysate was not accompanied by a reduction in inflammation, as assessed by plasma levels of CRP and IL-6, in either study; whereas, reductions in CRP and IL-6 were reported for all the studies in which an improvement in ESA utilization was found [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18,20-23,25,26\">",
"     18,20-23,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Beta2-microglobulin and dialysis-related amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of ultrapure dialysate has been associated with a reduction in predialysis serum beta2-microglobulin concentrations in the absence of any change in dialyzer, blood flow rate, or treatment time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/21,24,29\">",
"     21,24,29",
"    </a>",
"    ]. While the decrease in serum beta2-microglobulin concentration is small (approximately 3 to 5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    for patients treated with high-flux dialyzers), there is some indirect evidence from retrospective studies that dialysate quality has an impact on outcomes associated with retention of beta2-microglobulin in end-stage kidney failure. As an example, the incidence of carpal tunnel syndrome was evaluated in 226 patients from two dialysis centers, one of which used ultrapure dialysate, while the other used standard dialysate. At one center, only 2 of 84 patients treated only with ultrapure dialysate for 6.1 &plusmn; 3.2 years developed carpal tunnel syndrome; at the other center, carpal tunnel syndrome developed in 24 of 103 patients treated only with standard dialysate for 6.0 &plusmn; 5.9 years (p &lt;0.05 by Kaplan-Meier actuarial survival) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of a retrospective analysis also support a role for dialysate quality in slowing the development of beta2-microglobulin amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/32\">",
"     32",
"    </a>",
"    ]. These investigators compared the prevalence of amyloidosis in 89 patients treated for more than 10 years in 16 centers with dialysate that consistently met the requirements for standard dialysate (median bacterial count of 65",
"    <span class=\"nowrap\">",
"     CFU/mL)",
"    </span>",
"    or dialysate that was intermittently contaminated by bacteria at a level greater than 200",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    (median bacterial count of 550",
"    <span class=\"nowrap\">",
"     CFU/mL).",
"    </span>",
"    The prevalence of both carpal tunnel syndrome and arthropathy was significantly greater in the patients treated with contaminated dialysate (78 versus 39 percent for carpal tunnel syndrome and 61 versus 34 percent for arthropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to understand how a small decrease in serum beta2-microglobulin concentration could result in these changes in beta2-microglobulin amyloidosis. However, it is also reported that use of ultrapure dialysate is associated with a reduction in pentosidine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/24,27\">",
"     24,27",
"    </a>",
"    ], which has been implicated in the formation of beta2-microglobulin amyloid fibrils [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/33\">",
"     33",
"    </a>",
"    ], suggesting a more complex relationship between dialysate quality and beta2-microglobulin amyloidosis.",
"   </p>",
"   <p>",
"    Based on these observations, we suggest that ultrapure dialysate, along with other modalities (particularly high flux dialyzers and convective therapies), should be considered part of the strategy for delaying the onset of dialysis-related amyloidosis. Whether or not it can be useful in patients with established dialysis-related amyloid is far less clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is a common finding in hemodialysis patients. Conflicting findings have been reported concerning the use of ultrapure dialysate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some studies, it has been associated with improvements in nutritional status, including increases in serum albumin [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18,21,23,29\">",
"       18,21,23,29",
"      </a>",
"      ] and muscle mass [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18,29\">",
"       18,29",
"      </a>",
"      ]. Serum albumin has been reported to increase by 0.2 to 0.3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      over a 12-month period [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18,21,29\">",
"       18,21,29",
"      </a>",
"      ], together with increases in dry weight [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18\">",
"       18",
"      </a>",
"      ], mid-arm muscle circumference [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/18\">",
"       18",
"      </a>",
"      ], and creatinine generation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, not all studies have found an association between the use of ultrapure dialysate and an improvement in nutritional status. There are several reports of no change in serum albumin concentration over the 6 to 12 months following the introduction of ultrapure dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/24,27,28\">",
"       24,27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with anemia correction, there is no clear explanation for these disparate findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ultrapure dialysate also has been associated with a reduction in cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/34\">",
"     34",
"    </a>",
"    ], an improved response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/35\">",
"     35",
"    </a>",
"    ], improvements in dyslipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], and a slower rate of loss of residual renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/38\">",
"     38",
"    </a>",
"    ]. Four of these reports [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/34-36,38\">",
"     34-36,38",
"    </a>",
"    ] are from a single center, while the fifth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/37\">",
"     37",
"    </a>",
"    ] compared patients from two dialysis centers, one using ultrapure dialysate and the other standard dialysate. Further studies are needed to confirm these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRODUCTION OF ULTRAPURE DIALYSATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful strategies for routine production of dialysate that meets the current requirements for microbiological quality are well established [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=see_link\">",
"     \"Maintaining water quality for hemodialysis\"",
"    </a>",
"    .) These strategies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention to the design of the treated water distribution system to avoid areas of stagnation",
"     </li>",
"     <li>",
"      Attention to the preparation of concentrates, with particular emphasis on bicarbonate concentrate, which provides a good medium for bacterial proliferation",
"     </li>",
"     <li>",
"      Frequent disinfection of the treated water distribution system and dialysis machines on a schedule designed to minimize bacterial proliferation and biofilm formation in the fluid pathways.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dialysis machine can be a significant source of microbiological contaminants because its complex fluid pathways provide many opportunities for biofilm formation and, once formed, biofilm can be difficult to eliminate. Although contemporary machines are better designed for hygiene, following the machine manufacturer's instructions for cleaning and disinfecting the machine is an important part of maintaining dialysate quality. In general, the water line that connects the dialysis machine to the treated water distribution loop is not disinfected when the dialysis machine undergoes routine cleaning and disinfection according to the manufacturer's instructions; separate measures should be taken to ensure that the water line is also disinfected.",
"   </p>",
"   <p>",
"    Starting with dialysate that meets current quality recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], ultrapure dialysate can be produced by an additional step of filtration with a bacteria- and endotoxin-retentive filter immediately before the dialysate enters the dialyzer. Several of the membranes currently used for hemodialysis provide an excellent barrier to bacteria- and cytokine-inducing substances in dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], and most contemporary dialysis machines are designed so that such a filter can be installed as an integral part of the dialysate pathway. These filters are incorporated in the dialysate pathway in such a way that they are disinfected when the dialysis machine is disinfected according to the manufacturer's instructions.",
"   </p>",
"   <p>",
"    Not all dialysis membranes demonstrate the same capacity for removal of microbiological contaminants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/42\">",
"     42",
"    </a>",
"    ]. Therefore, only a filter that the manufacturer has validated to remove bacteria and endotoxin for a given period of time or number of dialysis treatments, even with repeated disinfection, should be used for the final filtration step in the preparation of ultrapure dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MONITORING DIALYSATE QUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of a system used to prepare ultrapure dialysate is monitored by cultures and endotoxin measurements on samples obtained immediately before system disinfection, since these samples should represent worst-case conditions. Sensitive methods are needed to make these measurements and, as described below, it is important to remember that current assays provide only limited information on the full spectrum of bacteria and microbial products in dialysate.",
"   </p>",
"   <p>",
"    Currently, the microbiological quality of dialysate is defined in terms of maximum levels for bacteria and endotoxin. Until 2010, the recommendation in the United States was to use tryptic soy agar and incubation at 35 to 37&ordm;C for 48 hours to determine the level of bacterial contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/43\">",
"     43",
"    </a>",
"    ]. Those culturing conditions are not optimal for recovery of the bacteria that contaminate purified water. Use of different culture media, such as Reasoner's 2A or tryptone glucose extract agar, together with incubation at room temperature for longer times, can result in colony counts that are an order of magnitude or more greater than those obtained with the method currently specified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/16,44\">",
"     16,44",
"    </a>",
"    ]. In November 2010, these more stringent culturing conditions, which were already in use in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/1,15\">",
"     1,15",
"    </a>",
"    ], were also adopted as the recommended method in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maximum allowable level of bacteria in ultrapure dialysate is 100",
"    <span class=\"nowrap\">",
"     CFU/L.",
"    </span>",
"    Conventional methods in which 1 mL of sample is applied to the culture plate have a lower limit of detection that is 1",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    at best, well above the limit for ultrapure. Strict compliance with the criterion for bacterial contamination in ultrapure dialysate can only be demonstrated by using the membrane filtration method with a sample size of at least 100 mL. Even then, organisms such as mycobacteria, fungi, and yeasts may not be detected, and cultures of fluid provide little information about organisms that may be present in biofilm on fluid-contacting surfaces.",
"   </p>",
"   <p>",
"    Endotoxin levels are measured with the Limulus amebocyte lysate (LAL) assay. Standard gel clot versions of this assay are capable of detecting endotoxin to 0.015",
"    <span class=\"nowrap\">",
"     EU/mL,",
"    </span>",
"    well below the maximum concentration of 0.5",
"    <span class=\"nowrap\">",
"     EU/mL",
"    </span>",
"    currently recommended in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/2,4,43\">",
"     2,4,43",
"    </a>",
"    ], and adequate to demonstrate that dialysate meets the endotoxin criterion for ultrapure. However, the LAL assay does not detect other pro-inflammatory bacterial products such as peptidoglycans and fragments of bacterial DNA. In one study, for example, 9.1 percent of 230 samples of dialysate (which were ultrapure according to the endotoxin criterion) induced IL-1b production in THP-1 cells using an assay that was sensitive to both peptidoglycans and bacterial DNA fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/45\">",
"     45",
"    </a>",
"    ]. The presence of bacterial DNA fragments in dialysate has also been associated with increased plasma concentrations of CRP and IL-6 in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/6\">",
"     6",
"    </a>",
"    ]. An alternative to the LAL assay, which uses silkworm larvae as the test reagent, can be used to determine levels of peptidoglycans in dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3383/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The inflammatory state may be an important contributor to the long-term morbidity associated with hemodialysis. Aspects of the hemodialysis procedure, particularly the low levels of microbiological contaminants in the dialysate, may act as inflammatory stimuli.",
"     </li>",
"     <li>",
"      The use of dialysate of much higher microbiological purity than is currently required has been recommended for routine hemodialysis. This \"ultrapure\" dialysate is commonly defined as having a bacterial count less than 100",
"      <span class=\"nowrap\">",
"       CFU/L",
"      </span>",
"      and an endotoxin content less than 0.03",
"      <span class=\"nowrap\">",
"       EU/mL",
"      </span>",
"      measured by the Limulus amebocyte lysate assay. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are insufficient data to definitively show that ultrapure dialysate reduces inflammation in hemodialysis patients, although the preponderance of data supports that conclusion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With respect to clinical outcomes, the overall finding of generally small, mostly observational studies is that ultrapure dialysate mitigates some of the long-term morbidity associated with hemodialysis. The most common findings are that the use of ultrapure dialysate is associated with improvements in anemia correction and nutritional status. To help prevent dialysis-related amyloidosis, we suggest the use of ultrapure dialysate rather than conventional dialysate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For prevention of dialysis-related amyloidosis, ultrapure dialysate should also be used in combination with other modalities, particularly high flux dialyzers and convective therapies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strategies for routine production of dialysate include attention to the design of the treated water distribution system to avoid areas of stagnation, attention to the preparation of concentrates, and frequent disinfection of the treated water distribution system and dialysis machines. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Production of ultrapure dialysate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The performance of a system used to prepare ultrapure dialysate is monitored using sensitive culturing methods and endotoxin measurements on samples obtained immediately before system disinfection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring dialysate quality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/1\">",
"      European Renal Association &mdash; European Dialysis and Transplant Association. European Best Practice Guidelines for Haemodialysis (Part I), Section IV: Dialysis fluid purity. Nephrol Dial Transplant 2002; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/2\">",
"      Ward, RA. Worldwide water standards for hemodialysis. Hemodial Int 2007; 11:S18.",
"     </a>",
"    </li>",
"    <li>",
"     International Organization for Standardization. Quality of dialysis fluid for hemodialysis and related therapies (ANSI/AAMI/ISO 11663:2009). Arlington, VA, Associaltion for the Advancement of Medical Instrumentation, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/4\">",
"      Tsuchida K, Takemoto Y, Yamagami S, et al. Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and limulus amebocyte lysate methods. Nephron 1997; 75:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/5\">",
"      Schindler R, Beck W, Deppisch R, et al. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J Am Soc Nephrol 2004; 15:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/6\">",
"      Bossola M, Sanguinetti M, Scribano D, et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/7\">",
"      Weber V, Linsberger I, Rossmanith E, et al. Pyrogen transfer across high- and low-flux hemodialysis membranes. Artif Organs 2004; 28:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/8\">",
"      Lonnemann G, Behme TC, Lenzner B, et al. Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria. Kidney Int 1992; 42:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/9\">",
"      Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/10\">",
"      Herbelin A, Ure&ntilde;a P, Nguyen AT, et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/11\">",
"      Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 2004; 8:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/12\">",
"      Pecoits-Filho R, Heimb&uuml;rger O, B&aacute;r&aacute;ny P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/13\">",
"      Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/14\">",
"      Lonnemann G. Chronic inflammation in hemodialysis: the role of contaminated dialysate. Blood Purif 2000; 18:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/15\">",
"      Kawanishi H, Masakane I, Tomo T. The new standard of fluids for hemodialysis in Japan. Blood Purif 2009; 27 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/16\">",
"      Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs 1999; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/17\">",
"      Ledebo I. On-line preparation of solutions for dialysis: practical aspects versus safety and regulations. J Am Soc Nephrol 2002; 13 Suppl 1:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/18\">",
"      Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/19\">",
"      Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/20\">",
"      Matsuhashi N, Yoshioka T. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients. Nephron 2002; 92:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/21\">",
"      Arizono K, Nomura K, Motoyama T, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 2004; 22 Suppl 2:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/22\">",
"      Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/23\">",
"      Rahmati MA, Homel P, Hoenich NA, et al. The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. Int J Artif Organs 2004; 27:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/24\">",
"      Furuya R, Kumagai H, Takahashi M, et al. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005; 23:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/25\">",
"      Molina M, Navarro MJ, Palacios ME, et al. [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis]. Nefrologia 2007; 27:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/26\">",
"      Go I, Takemoto Y, Tsuchida K, et al. The effect of ultrapure dialysate on improving renal anemia. Osaka City Med J 2007; 53:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/27\">",
"      Izuhara Y, Miyata T, Saito K, et al. Ultrapure dialysate decreases plasma pentosidine, a marker of \"carbonyl stress\". Am J Kidney Dis 2004; 43:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/28\">",
"      Lamas JM, Alonso M, Sastre F, et al. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study. Nephrol Dial Transplant 2006; 21:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/29\">",
"      Ouseph R, Jones S, Dhananjaya N, Ward RA. Use of ultrafiltered dialysate is associated with improvements in haemodialysis-associated morbidity in patients treated with reused dialysers. Nephrol Dial Transplant 2007; 22:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/30\">",
"      Kaysen GA, Dubin JA, M&uuml;ller HG, et al. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/31\">",
"      Baz M, Durand C, Ragon A, et al. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/32\">",
"      Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000; 15:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/33\">",
"      Miyata T, Taneda S, Kawai R, et al. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci U S A 1996; 93:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/34\">",
"      Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron 2002; 91:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/35\">",
"      Schiffl H, Wendinger H, Lang SM. Ultrapure dialysis fluid and response to hepatitis B vaccine. Nephron 2002; 91:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/36\">",
"      Schiffl H, Lang SM. Effects of dialysis purity on uremic dyslipidemia. Ther Apher Dial 2010; 14:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/37\">",
"      Honda H, Suzuki H, Hosaka N, et al. Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism. Blood Purif 2009; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/38\">",
"      Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/39\">",
"      Penne EL, Visser L, van den Dorpel MA, et al. Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online hemodiafiltration in routine clinical practice. Kidney Int 2009; 76:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/40\">",
"      Ward RA. Quality management of dialysis fluid for online convective therapies. Contrib Nephrol 2011; 168:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/41\">",
"      Lonnemann G, Mahiout A, Schindler R, Colton CK. Pyrogen retention by the polyamide membranes. Contrib Nephrol 1992; 96:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/42\">",
"      Bommer J, Becker KP, Urbaschek R. Potential transfer of endotoxin across high-flux polysulfone membranes. J Am Soc Nephrol 1996; 7:883.",
"     </a>",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Dialysate for hemodialysis (ANSI/AAMI RD52:2004). Arlington, VA, Association for the Advancement of Medical Instrumentation, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/44\">",
"      van der Linde K, Lim BT, Rondeel JM, et al. Improved bacteriological surveillance of haemodialysis fluids: a comparison between Tryptic soy agar and Reasoner's 2A media. Nephrol Dial Transplant 1999; 14:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3383/abstract/45\">",
"      Glorieux G, Schepers E, Schindler R, et al. A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrol Dial Transplant 2009; 24:548.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1948 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3383=[""].join("\n");
var outline_f3_19_3383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSOCIATION BETWEEN LOW LEVELS OF DIALYSATE CONTAMINATION AND INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anemia correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Beta2-microglobulin and dialysis-related amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRODUCTION OF ULTRAPURE DIALYSATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MONITORING DIALYSATE QUALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30330?source=related_link\">",
"      Alternative renal replacement therapies in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=related_link\">",
"      Contaminants in water used for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10775?source=related_link\">",
"      Maintaining water quality for hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_19_3384="Overview of biologic agents in the rheumatic diseases";
var content_f3_19_3384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of biologic agents in the rheumatic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3384/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3384/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3384/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3384/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/19/3384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the late 1990s, advances in molecular biology have led to a variety of new treatment approaches to rheumatoid arthritis and other systemic inflammatory diseases associated with autoimmunity. The major biologic approaches in clinical use include agents that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interfere with cytokine function",
"     </li>",
"     <li>",
"      Inhibit the &ldquo;second signal&rdquo; required for T-cell activation",
"     </li>",
"     <li>",
"      Deplete B cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of biologic agents used in the management of patients with rheumatic disorders is presented here. The role of cytokines in the immune system and in rheumatic disorders, the management strategies for individual diseases, and the adverse effects of tumor necrosis factor (TNF)-alpha inhibitors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=see_link\">",
"     \"Cytokine networks in rheumatic diseases: Implications for therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link\">",
"     \"Role of cytokines in the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TH1 AND TH2 CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;T helper (Th) cell subsets secrete specific cytokines, which, in turn, influence the development and perpetuation of systemic inflammation. Th cells and their cytokines can be categorized into two general subsets, termed Th1 and Th2. The cytokines generated by Th1 or Th2 cells inhibit the cellular function of the other phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/1\">",
"     1",
"    </a>",
"    ]. As examples, interferon-gamma and interleukin (IL)-12, which are produced by Th1 cells, inhibit Th2 cell proliferation, and IL-4 and IL-10, which are produced by Th2 cells, inhibit Th1 cytokine production.",
"   </p>",
"   <p>",
"    The concept that specific types of immune responses are dominated exclusively by Th1 or Th2 profiles is recognized as too simplistic to explain any rheumatic disease entirely. However, many biologic therapies have been developed for the purpose of targeting either the downregulation of proinflammatory Th1 responses or the upregulation of antiinflammatory Th2 cytokine production. Thus, the",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    paradigm is discussed briefly below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Th1 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th1 lymphocytes participate in a broad variety of inflammatory responses, including cell-mediated inflammation in rheumatoid arthritis, psoriasis, psoriatic arthritis, acute allograft rejection, graft-versus-host disease, and others. The list of proinflammatory mediators produced by Th1 cells includes but is not limited to the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interleukin (IL)-2",
"     </li>",
"     <li>",
"      Interferon gamma",
"     </li>",
"     <li>",
"      TNF",
"     </li>",
"     <li>",
"      IL-12",
"     </li>",
"     <li>",
"      IL-15",
"     </li>",
"     <li>",
"      IL-18",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Th2 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th2 lymphocytes stimulate antibody production by B cells and augment eosinophil responses. The activation of Th2 cells contributes to the development of chronic graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The list of mediators produced by Th2 cells includes but is not limited to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IL-4",
"     </li>",
"     <li>",
"      IL-5",
"     </li>",
"     <li>",
"      IL-9",
"     </li>",
"     <li>",
"      IL-10",
"     </li>",
"     <li>",
"      IL-13",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Downregulation of Th1 cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor necrosis factor (TNF) and interleukin (IL)-1 beta are major proinflammatory cytokines involved in the pathogenesis of rheumatoid arthritis and certain other chronic inflammatory diseases. When secreted by synovial macrophages, TNF and IL-1 stimulate synovial cells to proliferate and synthesize collagenase, thereby degrading cartilage, stimulating bone resorption, and inhibiting proteoglycan synthesis.",
"   </p>",
"   <p>",
"    TNF and IL-1 induce the expression of cellular adhesion molecules, thereby resulting in further inflammatory cell recruitment and in the release of additional cytokines. As an example, TNF secretion stimulates the release of IL-1, IL-6, and arachidonic acid metabolites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The significant role of IL-1 in the pathogenesis of RA and other forms of arthritis is supported by the finding of increased levels of both IL-1 and its messenger RNA (mRNA) in the synovium and synovial fluid. IL-1 has also been demonstrated in macrophages at the junction of the cartilage and pannus and at sites of maximal cartilage and bone destruction and may, therefore, be an important mediator of osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Upregulation of Th2 cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, therapies designed to upregulate or augment the function of Th2 cytokines have been less successful in clinical trials than have interventions that target Th1 cytokine inhibition, and no specific modulators of Th2 cytokine function are in clinical use for the treatment of rheumatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANTICYTOKINE APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several specific anticytokine therapies for the treatment of RA have been introduced into clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nomenclature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abbreviations placed at the ends of the names of therapeutic agents convey specific information relating to their structure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;-cept&rdquo; refers to fusion of a receptor to the Fc part of human IgG1",
"     </li>",
"     <li>",
"      &ldquo;-mab&rdquo; indicates a monoclonal antibody (mAb)",
"     </li>",
"     <li>",
"      &ldquo;-ximab&rdquo; indicates a chimeric mAb",
"     </li>",
"     <li>",
"      &ldquo;-zumab&rdquo; indicates a humanized mAb",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Types of molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;To downregulate or inhibit the effector functions of cytokines in vivo, three general approaches have been used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soluble receptor antagonists [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Monoclonal antibodies to cytokines or their receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cell surface receptor antagonist proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Soluble receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soluble receptor antagonists are truncated forms of the cell surface receptor that are devoid of the transmembrane and intracytoplasmic domains. However, these molecules retain binding affinities that are comparable to those of full-length membrane-bound receptors. The prototypical soluble receptor antagonist is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a fusion protein comprised of the p75 TNF receptor linked to the Fc portion of human IgG1. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Etanercept'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=see_link\">",
"     \"Cytokine networks in rheumatic diseases: Implications for therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Soluble receptor molecules such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    bind their target cytokine while it is in serum, thereby inhibiting the cytokine&rsquo;s ability to interact with its cell surface receptors. Soluble fusion proteins must remain in the circulation for weeks in order to achieve their therapeutic effects. The half-life of etanercept is longer than that of the native soluble receptor.",
"   </p>",
"   <p>",
"    To increase the half-life of soluble receptors in the circulation, a variety of constructs have been employed. As an example, the fusion of the Fc receptor of human IgG1 to the effector portion of the molecule is designed to enhance the construct&rsquo;s stability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second approach to the downregulation of cytokine function has been the use of monoclonal antibodies (mAbs). In general, mAbs have a higher affinity for a given cytokine than do soluble receptors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ) that target the same molecule. mAbs have an additional theoretical advantage over soluble receptors in that they bind their target not only when it is free in the serum but also when it is bound to the cell surface.",
"   </p>",
"   <p>",
"    mAbs in clinical use consist of the Fc portion of human IgG1 and either chimeric or humanized Fab fragments. Examples of mAbs employed in the treatment of rheumatic disease are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    . Certolizumab, a polyethylene glycolated (PEGylated) Fab fragment that does not contain an Fc portion, has also been developed. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'TNF inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cell surface receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant cell surface receptor antagonists are biologically inactive proteins that compete with a cytokine for binding to the cytokine&rsquo;s membrane receptor. An example of a cell surface receptor antagonist in the rheumatic diseases is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , a recombinant antagonist of the IL-1 receptor. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'IL-1 inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Receptor antagonists must bind greater than 90 percent of the receptors on the cell surface in order to be effective. Because large doses of the antagonist are required for such an effect, these proteins are generally less efficient than TNF inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TNF INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five TNF inhibitors are approved for the treatment of selected rheumatic disease by the United States Food and Drug Administration. A 2008 systematic review of synthetic and biologic DMARD therapy for RA concluded that anti-TNF monotherapy was similar in efficacy to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    alone, while the combination of an anti-TNF agent with methotrexate reduced disease activity more and slowed radiographic progression to a greater extent than did anti-TNF monotherapy or methotrexate alone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is a soluble p75 TNF receptor fusion protein that consists of two p75 TNF receptors bound to the Fc portion of IgG. Thus, the medication is bivalent (one etanercept molecule binds two TNF molecules). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=see_link\">",
"     \"Cytokine networks in rheumatic diseases: Implications for therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is effective for the treatment of a number of forms of inflammatory arthritis and other conditions, including RA, psoriatic arthritis, and ankylosing spondylitis. It is administered once or twice weekly via subcutaneous injection. (See appropriate topic reviews on the treatment of specific diseases.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is a chimeric mAb directed against TNF. The term &ldquo;chimeric&rdquo; refers to the use of both murine and human components of the drug. With infliximab, the VK and VH domains of the antigen-binding portion of the molecule are murine, and the constant Fc domain is human. Infliximab is administered via intravenous infusion approximately every six weeks once a steady state has been achieved.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    is effective for the treatment of a number of forms of inflammatory arthritis, inflammatory bowel disease, and other conditions. (See appropriate topic reviews on the treatment of specific diseases.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    is a recombinant fully human mAb that is administered subcutaneously rather than by intravenous infusion. The recommended interval between administrations is every two weeks. Adalimumab is associated with a lower risk of anti-drug antibody formation compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , by virtue of its humanized construction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    has been approved for use in RA, psoriatic arthritis, ankylosing spondylitis, and Crohn&rsquo;s disease. (See appropriate topic reviews on the treatment of specific diseases.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Certolizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    (CZP) is a human anti-TNF-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol. It neutralizes membrane-associated and soluble TNF-alpha. CZP is administered every two weeks by subcutaneous injection, and dosing at four-week intervals can be considered for maintenance therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    has been approved for use in Crohn&rsquo;s disease and in rheumatoid arthritis. (See appropriate topic reviews on the treatment of specific diseases.)",
"   </p>",
"   <p>",
"    In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , certolizumab does not contain an Fc portion and, therefore, does not induce complement activation, antibody-dependent cellular cytotoxicity, or apoptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Golimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    is a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that neutralizes TNF-alpha activity. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF-alpha. It is administered once monthly by subcutaneous injection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    has been approved for use in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. (See appropriate topic reviews on the treatment of specific diseases.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     IL-1 INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-1 inhibitors have had a smaller impact on rheumatoid arthritis and most other forms of inflammatory arthritis compared with TNF inhibitors, but they play a crucial role in the treatment of autoinflammatory conditions such as the TNF receptor-1 associated periodic syndrome (TRAPS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=see_link\">",
"     \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IL-1 inhibition also has a role in the treatment of some patients with acute gouty arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of acute gout\", section on 'Interleukin-1 inhibition (investigational)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of approaches to IL-1 inhibition have been employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link&amp;anchor=H2#H2\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'IL-1 inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The agonist effects of IL-1 are partially regulated by IL-1 receptor antagonist protein (IL-1Ra), a naturally occurring glycoprotein inhibitor that binds the high affinity cell surface IL-1 receptor without activating it [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link\">",
"     \"Role of cytokines in the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monocytes and tissue macrophages are the predominant source of IL-1Ra. The effects of IL-1Ra include decreased prostaglandin production by synovial cells and chondrocytes, decreased matrix metalloproteinase production by activated synovial cells and articular chondrocytes, and reduction in the infiltration of joint tissues by mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     Anakinra",
"    </a>",
"    , a recombinant human IL-1Ra (rHuIL-1Ra), differs from the native human protein in that it is not glycosylated and has an additional N-terminal methionine. Anakinra is approved for the treatment of RA but is significantly less potent than TNF inhibitors in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. In addition, anakinra is NOT recommended in a combination regimen with a TNF inhibitor because of an increased frequency of serious adverse events, including serious infections [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link&amp;anchor=H3#H3\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Anakinra'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     Anakinra",
"    </a>",
"    may be more effective in the treatment of autoinflammatory conditions such as the TNF receptor-1 associated periodic syndrome (TRAPS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=see_link\">",
"     \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2717446\">",
"    <span class=\"h2\">",
"     Canakinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     Canakinumab",
"    </a>",
"    , another anti-interleukin-1&beta; monoclonal antibody with a longer half-life than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , has also been employed in settings in which IL-1 inhibition is beneficial (eg, acute gout in which contraindications to conventional therapies exist) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     IL-1Ra gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-1Ra gene therapy appears promising both for inflammatory arthritis and for osteoarthritis. The onset of murine collagen-induced arthritis was abrogated by transfection of knee synovial fibroblasts with the IL-1Ra gene [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/17\">",
"     17",
"    </a>",
"    ]. Based upon this and other encouraging animal model data [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/18\">",
"     18",
"    </a>",
"    ], studies evaluating gene therapy using retroviral constructs encoding human IL-1Ra are underway in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IL-1Ra gene therapy involves removing synovium from the joint of a patient awaiting total joint arthroplasty, transfecting it with the IL-1Ra gene, and reimplanting the synovium at the time of joint replacement. In nine patients with osteoarthritis awaiting metacarpophalangeal arthroplasty, the procedure was tolerated well, and expression of the transgene was documented [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     IL-1 trap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokine traps are high-affinity blockers of cytokine action that may offer a more potent means of inhibition than strategies proposed previously [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/21\">",
"     21",
"    </a>",
"    ]. IL-1 is among the first cytokines targeted by this approach.",
"   </p>",
"   <p>",
"    The IL-1 trap comprises the extracellular domains of the IL-1 receptor accessory protein and the human IL-1 receptor, arranged inline and fused to the Fc portion of human IgG1.",
"   </p>",
"   <p>",
"    The clinical utility of cytokine traps is under investigation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"     Rilonacept",
"    </a>",
"    , a long-acting IL-1 receptor fusion protein, has been evaluated in the treatment of cryopyrin-associated periodic syndromes and in patients with chronic gout. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link&amp;anchor=H10#H10\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Rilonacept (IL-1 trap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     IL-6 INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-6 has both proinflammatory and antiinflammatory effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/22\">",
"     22",
"    </a>",
"    ]. The cytokine has the ability to activate T cells, B cells, macrophages, and osteoclasts and is a pivotal mediator of the hepatic acute phase response.",
"   </p>",
"   <p>",
"    IL-6 binds to both soluble and membrane-bound receptors and leads to the transduction of intracellular signals through the interaction of this complex with gp130, mediating gene activation and a wide range of biologic activities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased synovial fluid IL-6 levels correlate with disease activity in RA, and circulating levels are elevated in children with systemic juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Tocilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    is a humanized anti-human IL-6 receptor antibody of the IgG1 subclass. The medication is made by grafting the complementarity determining regions of a mouse anti-human IL-6 receptor mAb onto human IgG1. Tocilizumab competes for both the membrane-bound and soluble forms of human IL-6 receptor, thereby inhibiting the binding of the native cytokine to its receptor and interfering with the cytokine&rsquo;s effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    has been approved for use in RA and, in some countries, is approved for juvenile idiopathic arthritis and Castleman&rsquo;s disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H23#H23\">",
"     \"Castleman's disease\", section on 'Inhibition of interleukin-6'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=see_link&amp;anchor=H12929866#H12929866\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\", section on 'IL-6 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COSTIMULATION BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activation of T cells by antigen presenting cells requires two distinct signals, binding of the T cell receptor-peptide-MHC II complex and binding of cell surface costimulatory molecules that provide the essential &ldquo;second signal&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two important costimulatory systems have been delineated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD28",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can bind to one of two other proteins, CD80 or CD86 (often referred to as",
"      <span class=\"nowrap\">",
"       B7-1/B7-2)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/26\">",
"       26",
"      </a>",
"      ]. CD28 and CTLA-4 appear to provide an activating signal and an inhibiting signal, respectively.",
"     </li>",
"     <li>",
"      CD40 binds to CD154 (also known as CD40 ligand, CD40L, or gp39) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These costimulatory molecules regulate T-cell activation and T-cell dependent B-cell function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link&amp;anchor=H12#H12\">",
"     \"Transplantation immunobiology\", section on 'T-cell costimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    (also called CTLA4-Ig) is a soluble fusion protein comprising CTLA-4 and the Fc portion of IgG1. It prevents CD28 from binding to its counter-receptor,",
"    <span class=\"nowrap\">",
"     CD80/CD86,",
"    </span>",
"    due to its higher affinity for",
"    <span class=\"nowrap\">",
"     CD80/CD86.",
"    </span>",
"    Administration of CTLA4-Ig or successful transfer of its gene prevents or ameliorates collagen-induced arthritis in mice, and it is beneficial in transplantation models [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    is approved for use in RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     B-CELL DEPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-cell depletion is emerging as a viable therapeutic approach to a variety of rheumatic diseases. Lymphocytes of the B-cell lineage undergo an orderly developmental process that includes the surface expression of CD20, a B lymphocyte-specific molecule that is present at the pre-B cell stage. Expression of CD20 on the cell surface is lost as B cells differentiate into plasma cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a B cell depleting monoclonal anti-CD20 antibody, comprised of both mouse and human portions. Rituximab causes B-cell depletion and may do so through one or more of the following antibody-dependent mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fc receptor gamma-mediated antibody-dependent cytotoxicity",
"     </li>",
"     <li>",
"      Antibody-dependent complement-mediated cell lysis",
"     </li>",
"     <li>",
"      Growth arrest",
"     </li>",
"     <li>",
"      B-cell apoptosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is uncertain which of these mechanisms is most important in the depletion of B cells in humans.",
"   </p>",
"   <p>",
"    The absence of CD20 protein expression on the surface of plasma cells accounts for the resistance of these long-lived antibody-producing cells to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . As a consequence of plasma cell resistance, overall immunoglobulin levels usually remain within the normal range, despite profound B-cell lymphopenia that persists for months following a single course of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest that levels of autoantibodies with important roles in the pathophysiology of specific diseases are affected by B-cell depletion. Examples include rheumatoid factor in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], anti-dsDNA antibodies in systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/34\">",
"     34",
"    </a>",
"    ], and antineutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3384/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major biologic approaches to treatment of the rheumatic diseases include agents that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interfere with cytokine function",
"     </li>",
"     <li>",
"      Inhibit the &ldquo;second signal&rdquo; required for T-cell activation",
"     </li>",
"     <li>",
"      Deplete B cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    T helper (Th) cell subsets secrete specific cytokines, which, in turn, influence the development and perpetuation of systemic inflammation. Th cells and their cytokines can be categorized into two general subsets, termed Th1 and Th2. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Th1 and Th2 cytokines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many biologic therapies have been developed for the purpose of targeting the downregulation of proinflammatory Th1 responses. Upregulation of antiinflammatory Th2 cytokine production does not appear to be effective.",
"   </p>",
"   <p>",
"    The following biologic treatment strategies are employed in rheumatic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TNF inhibition (see",
"      <a class=\"local\" href=\"#H13\">",
"       'TNF inhibition'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IL-1 inhibition (see",
"      <a class=\"local\" href=\"#H19\">",
"       'IL-1 inhibition'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IL-6 inhibition (see",
"      <a class=\"local\" href=\"#H23\">",
"       'IL-6 inhibition'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Costimulation blockade (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Costimulation blockade'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      B-cell depletion (see",
"      <a class=\"local\" href=\"#H27\">",
"       'B-cell depletion'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/1\">",
"      Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; 12:A49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/2\">",
"      Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 1998; 17:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/3\">",
"      Lamberg L. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest. JAMA 2003; 289:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/4\">",
"      Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991; 5:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/5\">",
"      Bendtzen K, Hansen MB, Ross C, et al. Cytokines and autoantibodies to cytokines. Stem Cells 1995; 13:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/6\">",
"      Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/7\">",
"      Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996; 87:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/8\">",
"      Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/9\">",
"      Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/10\">",
"      Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/11\">",
"      Smith RJ, Chin JE, Sam LM, Justen JM. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991; 34:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/12\">",
"      Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/13\">",
"      Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009; :CD005121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/14\">",
"      Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/15\">",
"      Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/16\">",
"      Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/17\">",
"      Bakker AC, Joosten LA, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/18\">",
"      Otani K, Nita I, Macaulay W, et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996; 156:3558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/19\">",
"      Evans CH, Robbins PD, Ghivizzani SC, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996; 7:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/20\">",
"      Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 2005; 102:8698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/21\">",
"      Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/22\">",
"      Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/23\">",
"      Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/24\">",
"      Miltenburg AM, van Laar JM, de Kuiper R, et al. Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation. Br J Rheumatol 1991; 30:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/25\">",
"      De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998; 25:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/26\">",
"      Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/27\">",
"      Foy TM, Aruffo A, Bajorath J, et al. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996; 14:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/28\">",
"      Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/29\">",
"      Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/30\">",
"      Quattrocchi E, Dallman MJ, Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum 2000; 43:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/31\">",
"      Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/32\">",
"      Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/33\">",
"      Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/34\">",
"      Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54:3612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/35\">",
"      Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/36\">",
"      Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3384/abstract/37\">",
"      Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7966 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3384=[""].join("\n");
var outline_f3_19_3384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TH1 AND TH2 CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Th1 cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Th2 cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Downregulation of Th1 cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Upregulation of Th2 cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANTICYTOKINE APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nomenclature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Types of molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Soluble receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cell surface receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TNF INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Certolizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Golimumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IL-1 INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anakinra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2717446\">",
"      Canakinumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      IL-1Ra gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      IL-1 trap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      IL-6 INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Tocilizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COSTIMULATION BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Abatacept",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      B-CELL DEPLETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=related_link\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_19_3385="Approach to the evaluation of older drivers";
var content_f3_19_3385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the evaluation of older drivers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3385/contributors\">",
"     Maryjoan D Ladden, PhD, RN, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3385/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/19/3385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/19/3385/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/19/3385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, the United States (US) census bureau noted that 12.9 percent of the US population is aged 65 or older [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/1\">",
"     1",
"    </a>",
"    ]. By the year 2020, it is predicted that 50 million people will fall into this age range, one-half of whom will be over age 75 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2010, approximately 15 percent of automobile drivers in the United States are aged 65 or older [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/3\">",
"     3",
"    </a>",
"    ] and it is estimated that 38 million licensed older drivers (over age 70 years) may be on the road in 2020 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older drivers have become front page news not only because of the aging of the population, but also because they are involved in more fatal car crashes per miles driven than any other age group except teenagers. Drivers over the age of 75 years also have more traffic violations and nonfatal collisions than younger drivers. Two of the most common violations, failure to yield the right of way and failure to obey a traffic sign, often lead to accidents at intersections where situations require a quick response, full peripheral vision, and interaction with other drivers.",
"   </p>",
"   <p>",
"    These observations have prompted individual states to consider legislation that would tighten license renewal requirements for older drivers. As an example, in 1999 the California state senate debated but did not pass the \"Brandi Jo\" bill, an amendment requiring drivers ages 75 years and older to take a written, vision, and road test at every renewal period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/5\">",
"     5",
"    </a>",
"    ]. The bill also proposed shortening the renewal periods from the usual every four years to every year after age 90.",
"   </p>",
"   <p>",
"    However, while statistics might suggest that severe restrictions should be imposed on older drivers, the task is not that simple. Driving is an important issue for older adults. The majority of Americans rely upon private automobiles for their transportation, and most older adults regard driving as critical to their independence and self-esteem. A cross-sectional telephone survey in the United States, conducted by the Centers for Disease Control and Prevention (CDC) in 2001-2003, found that among survey respondents (48 percent of those surveyed), 75 percent of adults aged 75 to 84 years, and 70 percent of adults aged 85 and older were current drivers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/3\">",
"     3",
"    </a>",
"    ]. Older adults who are forced to stop driving rely more upon their families, reduce their social activities, and often become depressed.",
"   </p>",
"   <p>",
"    Furthermore, despite a moderate decline in mental, motor, optic, and auditory functions with aging, many older people drive safely. Driving performance is usually impaired only after a considerable loss of function since most driving patterns are learned and become second nature. In addition, we often regulate our own driving as we age; seniors drive fewer miles, shorter distances, less at night, and seldom in rush hour. In the CDC survey, 82 percent of older drivers (&ge;age 75) reported that they limited driving for weather conditions, distance, or night [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/3\">",
"     3",
"    </a>",
"    ]. Interestingly, however, only 15 percent limited driving for medical reasons, and none for cognitive impairment. There is consensus among traffic safety experts that older drivers should be kept on the road as long as they can drive safely.",
"   </p>",
"   <p>",
"    No one wants to use chronological age as the sole indicator of driving ability, but it is difficult to otherwise determine whether an older person can drive safely. There is not currently one effective, easily administered test, or series of tests, to evaluate driving competence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Thus, the task of evaluating the older adult's functional capacity to drive often falls to their primary care provider, when a spouse or adult child asks \"Is my husband or father safe to drive?\" The difficult task then is to evaluate the older patient's functional capacity to drive, balancing public safety with patient autonomy. In a survey of family physicians in Canada, about one half of the respondents lacked confidence in their ability to assess driving fitness, and 75 percent felt that reporting a patient as unsafe would potentially undermine their relationship with the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AGE RELATED CHANGES AND DRIVING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the normal changes in vision, psychomotor ability, and cognitive status with aging, older people are more likely to have medical conditions that can affect driving performance. Several studies have attempted to identify the specific medical conditions and functional deficits that predict motor vehicle crashes or adverse driving events in the older population. The following factors have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of falls in the past one to two years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The presence of visual [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/14-17\">",
"       14-17",
"      </a>",
"      ] and cognitive deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A prior history of motor vehicle crashes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/17,20\">",
"       17,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Current use of medications such as tricyclic antidepressants and benzodiazepines [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/13,21\">",
"       13,21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of studies examining these factors utilized a self-reported history of adverse driving events. One prospective study of 1910 drivers aged 55 to 96, recruited at the time of driver's license renewal, evaluated these individuals with a battery of tests for mobility, vision, and cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/22\">",
"     22",
"    </a>",
"    ]. After follow-up of four to five years, the risk of at-fault motor vehicle accidents was found to approximately double with impaired performance on individual tests of agility, visual perception, and cognition, as well as with age &gt;78 years; male sex and history of falls also increased risk. One case-control study of 174 older drivers between 55 and 90 years of age identified four variables associated with at-fault car crashes: failed UFOV (useful field of view) test (OR 6.1), black race (OR 6.6), not taking a beta blocker (OR 4.3), and history of a fall in the past two years (OR 2.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/12\">",
"     12",
"    </a>",
"    ]. The association with race is questionable, however, since there were few blacks in the control population.",
"   </p>",
"   <p>",
"    In the Second Injury Control and Risk Survey conducted by the Centers for Disease Control in the United States between 2001 and 2003, self-reported motor vehicle crashes occurred more frequently in older adults who lived alone or who were men [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The variables most significantly associated with crashes were related to functional status and medications rather than the presence of medical diagnoses or chronological age. Failed UFOV, which evaluates several visual and cognitive processing domains as well as attentional capacity, has also been linked to crashes in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. Falling and car crashes have similar risk factors, such as the use of sedative or psychotropic medications, cognitive impairment, and balance and gait abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding that beta blocker use was associated with reduced odds of at-fault crashes had not been noted in previous studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/12\">",
"     12",
"    </a>",
"    ]. Although none of the medical conditions associated with beta blocker use were associated with crashes, the authors suggested that, as shown in other studies, beta blockers may reduce performance anxiety and tremor, thereby strengthening vehicle control in some older people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATING OLDER DRIVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of driving ability should be based on performance of objective measures, rather than age alone. Several areas of the history, physical examination, and functional assessment are particularly relevant. There are also resources available in the community to supplement the primary care clinician's driving evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pertinent medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although medical conditions alone have not been found to have a strong effect upon driving performance, a past or current history of ischemic heart disease, cerebrovascular disease, movement disorders, diabetes mellitus, epilepsy, sleep disorders, and arthritis should be evaluated during the primary care examination [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some acute conditions that impair consciousness, especially transient ischemic attacks, syncope, and seizures, make driving potentially dangerous [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/25\">",
"     25",
"    </a>",
"    ]. For patients with a recent history of these conditions, the clinician should recommend cessation of driving for some period of time until recovery is assured and the baseline level of functioning has returned (",
"    <a class=\"graphic graphic_table graphicRef62343 \" href=\"UTD.htm?14/32/14859\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Medications, alcohol, and other substances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older people (65 years and older) comprise approximately 13 percent of the United States population, but receive about 32 percent of the prescription drugs dispensed each year. In 1990 the Health Care Financing Administration (HCFA) estimated that an older person received an average of 17 to 20 prescription drugs per year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/26\">",
"     26",
"    </a>",
"    ]. The physiologic changes associated with aging affect drug absorption, distribution, and renal excretion.",
"   </p>",
"   <p>",
"    Thus, a careful history of prescription, over-the-counter, and herbal medications is important in all seniors. Medications with effects on the central nervous system, such as benzodiazepines, antihistamines, anticholinergics, and some tricyclic antidepressants, can be harmful alone and especially in combination. More than one-third of all benzodiazepine prescriptions are written for people ages 60 and older. The traffic accident risk increases by nearly 50 percent in the first week after starting benzodiazepine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/21\">",
"     21",
"    </a>",
"    ]. A population study of older drivers involved in traffic accidents resulting in hospitalization found a five-fold increased risk for serious accident associated with the use of benzodiazepines (OR 5.3); increased risk was also associated with use of antidepressants (OR 1.8) or opioids (OR 1.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One common approach to medication assessment in the primary care setting is to ask the older patient to bring all their medications, including prescription, over the counter, and herbals, in a \"brown bag\" to the visit. The contents of the \"brown bag\" can be reviewed with a nurse prior to the clinician visit to determine the older adult's understanding of the indications for use and side effects. In those adults using multiple medications, it is often helpful to have a pharmacist review the contents of the \"brown bag\" yearly for cost issues and drug interactions.",
"   </p>",
"   <p>",
"    The use of alcohol and other substances is hazardous for drivers of any age. However, the physiologic changes of aging such as a decrease in lean body mass and increase in adipose tissue, as well as the potential for multiple drug interactions, make this a significant issue for older drivers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Social history, including driving",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often clinicians are so focused upon managing the medical aspects of multiple chronic diseases that they forget to explore areas of the history that relate to the older person's quality of life in the community, such as social support, activities of daily living, alcohol use, and transportation. Social support is a critical element in maintaining health, recovering from acute illness, and managing chronic disease. Asking about family and social supports can provide insight into how the older adult is managing at home and what resources are available should",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    become ill.",
"   </p>",
"   <p>",
"    For all patients ages 65 and older, specific questions about driving should be included in the primary care history:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How did the older patient get to the primary care visit?",
"     </li>",
"     <li>",
"      How often and under what circumstances does",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      drive?",
"     </li>",
"     <li>",
"      Any traffic violations, accidents, or close calls within the past six months, year, two years?",
"     </li>",
"     <li>",
"      Any episodes of getting lost while driving?",
"     </li>",
"     <li>",
"      Does the older person feel comfortable and want to continue driving?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, asking who would be able to drive to appointments or for groceries if",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    became ill or was unable to drive will provide useful information about social support resources if driving became unadvisable. In some instances, the clinician may want to contact the family, with the older patient's consent, for their observations.",
"   </p>",
"   <p>",
"    Also, as with all patients who ride in cars, it is appropriate to ask about seatbelts and encourage their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The areas of the physical examination most closely related to driving safety are mobility and functional status [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/12,13,17\">",
"     12,13,17",
"    </a>",
"    ], visual attention [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/14-17\">",
"     14-17",
"    </a>",
"    ], and cognitive status [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The recommended functional assessment of older drivers is summarized in Table 2 (",
"    <a class=\"graphic graphic_table graphicRef71095 \" href=\"UTD.htm?29/63/30715\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging precipitates changes in muscle strength, reaction time, and mobility, particularly of the neck, shoulder, and wrist. Decreased muscle strength can significantly impact driving ability. Grip strength appears to decline after age 75, although exercise can help to avoid significant loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/29\">",
"     29",
"    </a>",
"    ]. Restrictions in neck, shoulder, and wrist movement, often caused by rheumatologic conditions, can restrict the field of view in traffic situations, as well as the ability to control the steering wheel.",
"   </p>",
"   <p>",
"    Psychomotor ability is not evaluated with a driver's license renewal, except in states that require on-the-road testing. Drivers with diminished strength, reaction time, or mobility may not pass the road test. Older drivers with limited flexibility can have their cars equipped with adaptive equipment, such as special mirrors or power assistive devices, to enhance their driving ability.",
"   </p>",
"   <p>",
"    Mobility issues relevant to driving can be assessed in several ways during the primary care visit.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate range of motion of the neck, shoulders, and wrists.",
"     </li>",
"     <li>",
"      Evaluate balance and gait with the Get Up and Go Test [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. In this brief and practical test, the older patient is asked to rise from a chair, walk 10 feet, turn around, walk back, and then sit down in the chair. The test is timed and usually takes 15 seconds. The clinician should observe the use of the arms or hands to assist the rise from the chair, the height and length of the steps, use of the arms when walking, balance and ease of the turnaround (the most unstable portion of the gait), and how easily the older patient sits down again. There are no established norms to score the test, but observation of these aspects of the older patient's performance during the Get Up and Go Test can provide important information on the risk for falls and driving problems.",
"     </li>",
"     <li>",
"      The functional reach test is another test for balance and fall risk that is easily administered in the primary care office [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/32\">",
"       32",
"      </a>",
"      ]. A yardstick is mounted to the wall. The patient stands close to the wall with feet flat on the floor and raises one arm parallel to the yardstick, with the arm at 90 degrees of shoulder flexion, the elbow extended, and the hand fisted. The patient is asked to keep the fist in line with the yardstick and lean forward as far as possible, without taking a step or falling forward. As the patient leans forward, the fist moves along the yardstick. If the starting and ending point of the fist is less than six inches, the patient is at a high risk of falling within the next 6 months.",
"     </li>",
"     <li>",
"      Measuring grip strength with a dynamometer can be useful for older drivers who have had a stroke. The general rule is that 35 pounds of strength in the dominant hand is necessary for safe driving [",
"      <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of visual impairment and blindness in older people is caused by age-related macular degeneration, glaucoma, cataracts, and diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/33\">",
"     33",
"    </a>",
"    ]. Age-related changes in vision that can affect driving include decreases in central visual acuity and peripheral vision, diminished ability to accommodate, and heightened sensitivity to glare [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/29\">",
"     29",
"    </a>",
"    ]. Over age 50, the total horizontal peripheral visual field declines from 170 degrees to 140 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/28\">",
"     28",
"    </a>",
"    ]. Drivers with deficits in peripheral vision have twice as many collisions as those with normal vision. Many older adults avoid driving at dusk and twilight because of these changes.",
"   </p>",
"   <p>",
"    Visual acuity and peripheral vision are evaluated in most states as part of the driver's license renewal process. Retesting visual acuity between the renewal periods is required only if there has been a driving incident. The most common acceptable requirements are a visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    in the better eye and 120 degrees of horizontal peripheral vision.",
"   </p>",
"   <p>",
"    In the primary care setting, the most effective measures for detecting significant age-related eye problems are the history, visual acuity testing, and fundoscopy. In addition to past and current medical history and medications, the specific visual history should include a family history of eye disease and the presence of current visual symptoms. Distance visual acuity can be evaluated with the Snellen chart. Near visual acuity can be measured with the Rosenbaum pocket vision screening card or by having the older patient read a newspaper or magazine held 14 inches (at arm's length) from the eyes; generally newspaper type is equivalent to",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    on the Snellen near visual acuity chart. Fundoscopic evaluation of the optic disc, macula, and red reflex will reveal macular degeneration, diabetic changes, glaucoma and cataracts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While visual acuity is critical to driving performance, peripheral vision and visual attention are more closely associated with motor vehicle crashes. As mentioned above, the Useful Field of View Test (UFOV: Visual Resources Inc., Bowling Green, KY) is a sensitive predictor of driving safety, with a reduction of 40 percent or more in the UFOV closely associated with crash involvement in older drivers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. The UFOV measures how well one can pay attention to a large area all at once, including how fast one can process visual targets on the screen and filter out irrelevant events in the environment to accomplish two tasks at one time. When there are concerns about visual acuity and the older adult's ability to drive, referral can be made to a rehabilitation setting or specialist for UFOV testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing impairment is the third most prevalent chronic health condition in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/34\">",
"     34",
"    </a>",
"    ]. Significant hearing loss can affect driving performance and safety. Screening for hearing loss should begin with the history, such as difficulties hearing the television and telephone or understanding speech in a crowded room, and otoscopic inspection for cerumen impaction. The whisper test can be used as a brief screening tool to determine whether there is a difference in hearing in each ear and whether referral for formal audiologic examination is necessary. In this test, one ear is occluded and the older patient is asked to repeat the words or numbers whispered softly by the clinician standing one to two feet away, usually to the back of the patient. The whispered words or numbers used for the test should be those with equally accented syllables, such as baseball or twenty-two [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cognitive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fourteen percent of community-residing older adults between 75 and 84 years of age, and over 20 percent of those 85 years and older, have cognitive impairments. While older patients with cognitive impairment tend to self limit their driving, a significant number still continue to drive, and the cognitive impairment is frequently not recognized by their physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of drivers with dementia found consistent evidence for poorer performance on road or simulated tests of driving, compared with drivers without cognitive impairment, but did not find consistent reports of higher crash rates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/37\">",
"     37",
"    </a>",
"    ]. However, statistics of motor vehicle accidents may under-represent the risk since older patients substantially reduce their driving [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/38\">",
"     38",
"    </a>",
"    ]. In another systematic review, 76 to 85 percent of subjects with mild dementia (Clinical Dementia Rating [CDR] scale of 0.5 to 1.0) were found to be safe drivers by a road driving test subjects, but were significantly more likely to fail an on-road driving test than those without dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/10\">",
"     10",
"    </a>",
"    ]. Studies of driving evaluations consistently demonstrate worse performance in patients with dementia compared with age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether patients with mild cognitive impairment should be allowed to drive is the subject of much debate but limited consensus. Mild cognitive impairment increases the risk for unsafe driving but, alone, does not establish that a patient is an unsafe driver. Studies are not available to determine whether compensatory strategies for patients with cognitive impairment (driving with co-pilots, restricted licensing, education) are effective in improving driving safety. Cognitive training may be effective for those with minimal cognitive impairment, however. In a randomized trial of cognitive training for older subjects with no or mild impairment (MMSE &ge;23), those randomized to participate in 8 to 10 sessions of training to improve speed-of-processing and reasoning had lower rates of at-fault motor vehicle collisions at six years compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the primary care setting, evaluation of cognitive function should begin with the history. Mental status changes may become apparent in the older adult's responses to areas of the medical and social history. However, even signs of moderately severe dementia can be subtle and difficult to detect without formal cognitive testing. &nbsp;A systematic review of studies that evaluated predictors of driving capacity in persons with dementia found that the Clinical Dementia Rating (CDR) scale (",
"    <a class=\"graphic graphic_table graphicRef53706 \" href=\"UTD.htm?0/0/2\">",
"     table 3",
"    </a>",
"    ) had the best evidence of utility in evaluating driving safety [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An American Academy of Neurology practice parameter suggests an algorithm for evaluating driving safety in patients with dementia based upon the clinical dementia rating (CDR) (",
"    <a class=\"graphic graphic_table graphicRef53706 \" href=\"UTD.htm?0/0/2\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a CDR = 2 are at high risk for unsafe driving. Patients and families should be counselled to stop driving and interventions should be made pursuant to state guidelines.",
"     </li>",
"     <li>",
"      Patients with a CDR = 0.5 or 1 are at intermediate risk for unsafe driving. Considering this along with the other risk factors noted above, patients and families should be encouraged to develop alternative sources of transportation, to consider voluntary surrender of driving privileges, limiting driving to familiar routes during daylight hours, and to consider referral for a professional driving evaluation. A substantial proportion (41 to 85 percent) of patients in this CDR range will be judged to be safe drivers by an on-road driving evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative testing that may be used includes tests of mental status, the Mini-Mental State Exam (MMSE) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/40\">",
"     40",
"    </a>",
"    ], and other tests of dementia (Trails A, Trails B [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/41\">",
"     41",
"    </a>",
"    ], clock drawing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/42\">",
"     42",
"    </a>",
"    ], and copying intersecting geometric figures) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/19,43-45\">",
"     19,43-45",
"    </a>",
"    ]. Scores on the MMSE should be interpreted carefully as the patient's level of formal education can affect the score (",
"    <a class=\"graphic graphic_figure graphicRef79818 \" href=\"UTD.htm?22/60/23502\">",
"     figure 1",
"    </a>",
"    ). The maximum score on the MMSE is 30. However, validated cutoff scores to be used to advise older drivers that they should cease driving, or be referred for formal driving evaluation, have not been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/8\">",
"     8",
"    </a>",
"    ]. A 2010 guideline from the American Academy of Neurology suggests that an MMSE score &le;24 is useful in identifying patients at increased risk for unsafe driving, but cites conflicting data correlating MMSE scores with unsafe driving and crashes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Mini-Mental State Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mandatory reporting of a moderate or severe dementia is required in some states in the US (eg, California, Pennsylvania) as well as certain provinces in Canada and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/46\">",
"     46",
"    </a>",
"    ]. Although a number of driving safety tests have been suggested, no guidelines have been broadly implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/18,47,48\">",
"     18,47,48",
"    </a>",
"    ]. Local programs may exist to evaluate these patients with neuropsychological and roadside tests. In the absence of these programs, the department of motor vehicles will often perform roadside testing, but patients must be informed that even if they pass they will need to be retested at regular intervals as their disease progresses. Families must be warned about potential liability for accidents. They may need to take possession of car keys, or even the cars, and restrict all driving.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Multimodal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research is ongoing to identify specific functional tests that correlate with formal driving assessment and can be used to determine driving safety. One report, based on multivariate analysis of a number of tests for vision, cognitive ability, and motor performance, found that assessment for color choice reaction time, postural sway, motion sensitivity and self-reported distance driven regularly could classify drivers as safe or unsafe (based on road testing) with a sensitivity of 91 percent and specificity of 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/49\">",
"     49",
"    </a>",
"    ]. This test battery will need further validation in other populations of older drivers to confirm its reliability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FAMILY AND CLINICIAN RESOURCES ABOUT OLDER DRIVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is challenging to identify the unsafe older driver during the primary care visit, once the driver is identified, the clinician and the family often find it even more difficult to talk with the older driver about their concerns. Many clinicians are also unsure of what to do if the primary care evaluation suggests that the older patient should stop driving.",
"   </p>",
"   <p>",
"    In a 1997 New York State survey of families and caregivers of older drivers, over 70 percent of the family members reported that they had been concerned over one year about driving safety (",
"    <a class=\"external\" href=\"file://www.aging.ny.gov/\">",
"     www.aging.ny.gov/",
"    </a>",
"    ). The first indication came from watching the older driver, damage to the car, comments from passengers, or an accident. Over 50 percent of the family members reported that the older driver was also having problems with other activities of daily living. They had noticed a recent event, such as an illness or hospitalization, that signaled a decrease in driving performance. Surprisingly, 60 percent of the family members reported that they were not able to discuss the issue with the older driver or to intervene to stop the older adult from driving.",
"   </p>",
"   <p>",
"    These family members described three areas in which the primary care clinician could help them intervene with the older driver. First, assessment of the older adult's health and functional status would provide an objective assessment of medical issues that might interfere with driving. Second, the family members desired support from the clinician to discuss their concerns with the older driver. And finally, they wanted information about areas such as independent evaluation of on-the-road driving competence and alternative resources for transportation in the community.",
"   </p>",
"   <p>",
"    The primary care history and physical examination can provide critical information about age-related problems that may affect driving performance. However, often even after a complete examination with special attention to these areas, the answer to the question, \"Is my husband or dad safe to drive?\" is still not clear. At this point, if the clinician suspects that the older adult may not be safe to drive, and the patient, family, and the clinician desire an objective assessment, several resources are available to supplement the primary care driving evaluation.",
"   </p>",
"   <p>",
"    The Alzheimer's Association Web site (",
"    <a class=\"external\" href=\"file://www.alz.org/\">",
"     www.alz.org",
"    </a>",
"    ) is an excellent resource for clinicians, patients, and families on many aspects of Alzheimer dementia, including driving. They describe the warning signs of unsafe driving, such as forgetting how to locate familiar places, failure to obey traffic signals, making slow or poor decisions, driving at an inappropriate speed, and becoming angry and confused while driving. These signs can be useful for the older adult and the family to identify the unsafe older driver.",
"   </p>",
"   <p>",
"    The organization suggests the following approaches for caregivers who are unable to convince the older adult to stop driving. First, control the older adult's access to the car by hiding the keys, disabling the car by removing the battery or the distributor cap, or parking the car on another block or in another driveway. Second, arrange for substitute transportation. Third, ask the clinician to write a prescription for \"Do Not Drive,\" and finally, arrange on-the-road evaluation by the state department of motor vehicles. The latter approach is truly a last resort as there are many implications in involving the state department of motor vehicles in the evaluation of older drivers.",
"   </p>",
"   <p>",
"    The American Association of Retired Persons (AARP) has an active older drivers program, 55 Alive, which offers an eight-hour class on driving safety for a nominal charge. Over five million older drivers have completed the program since it was developed in 1979. Graduates of the program who live in 34 states and the District of Columbia are eligible to receive a multi-year car insurance discount. The AARP Web site (",
"    <a class=\"external\" href=\"file://www.aarp.org/\">",
"     www.aarp.org",
"    </a>",
"    ) contains information about their driving programs, as well as a helpful \"Close Call Quiz\" that can be used by older drivers as a self assessment. The AARP program and a more general class sponsored by the American Automobile Association (AAA) are helpful in reviewing the rules of driving and helping older drivers self assess their driving knowledge. However, these programs do not evaluate the most critical component of the driving evaluation, on-the-road performance. Many local driving schools will perform an on-the-road evaluation for a small fee. In addition, veterans' and rehabilitation hospitals also have driving programs available. The veterans' hospitals are free of charge for veterans.",
"   </p>",
"   <p>",
"    The American Geriatrics Society is also a good resource for clinicians and families. Their Web site (",
"    <a class=\"external\" href=\"file://www.americangeriatrics.org/\">",
"     www.americangeriatrics.org",
"    </a>",
"    ) contains information for clinicians on age-related issues as well as excellent patient education materials. The Patient Education Forum, Safe Driving for Seniors, is particularly useful in a question and answer format for older drivers.",
"   </p>",
"   <p>",
"    On-the-road driving evaluation is often the most effective way of convincing an older driver that he or she may not be safe to drive. This objective evaluation of driving performance takes the pressure off the family and the clinician who want to maintain a positive relationship with the older patient.",
"   </p>",
"   <p>",
"    Social workers and case managers can be very helpful in identifying other resources in the community and working with the older adult and family around transportation issues. Another strategy to use with resistant older drivers is to remind them that insurance companies may refuse to pay for damages that occur after their clinician recommends driving cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     US STATE LICENSE RENEWAL REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US public expects the states, through the department of motor vehicles or transportation safety, to detect, examine, and regulate problem drivers. Each state has different license renewal requirements, and most states have no procedures specific for age. Driving competency tests, usually vision and on-the-road exams, can be done after self or others report driving problems. It is difficult for the states to take an active role because the most common age-related issues that affect driving safety are multifactorial, and often occur between licensing periods.",
"   </p>",
"   <p>",
"    The most restrictive states, New Hampshire and Illinois, require residents who are 75 years and older to take vision and on-the-road tests each year to renew their license. Restrictions can also be placed on the license, such as \"daylight only\" or \"local area only.\" The District of Columbia, for example, requires a physician certification each renewal period. In 1996, California changed its driving policies regarding older adults with dementia. The California Division of Motor Vehicles requires that the licenses of older adults with moderately advanced dementia be revoked without testing. Florida, where there are many older drivers, is one of the least restrictive states; drivers ages 70 years and older can renew their license by mail for two renewal periods (ie, eight years), with only a vision test required at the third renewal.",
"   </p>",
"   <p>",
"    The issue of age-based testing is controversial. Those in favor say that routine testing should be mandatory starting with a certain age because many older adults are unwilling to recognize their limitations. However, those against are concerned about age discrimination and advocate that testing should be mandatory based upon driving history and performance, not solely on the basis of age. In those states with age-based mandatory testing, less than 5 percent of older drivers actually lose their license after the testing.",
"   </p>",
"   <p>",
"    A retrospective study that used a multivariate analysis to look at the relationship between fatal crashes and state laws in the United States found that for people aged 85 and older, states with in-person license renewal requirements were associated with a lower driver fatality rate (incident rate ratio 0.83, 95% CI 0.72-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/51\">",
"     51",
"    </a>",
"    ]. Requirements for in-person renewal in younger age groups did not reduce fatality rates. State-mandated vision tests, road tests, and more frequent license renewal for older drivers also did not reduce fatality rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LEGAL ISSUES IN EVALUATING OLDER DRIVERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13088552\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nationwide survey in the United States found that almost 30 percent of geriatricians did not know how to make a report in their state about an older patient with dementia who is a potentially dangerous driver [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, the courts have provided little clear guidance on this issue. Although lawsuits have been filed by innocent people who were injured as a result of an accident, the courts have been inconsistent in their findings against clinicians who allowed their potentially impaired patients to continue to drive. For the most part, the legal decisions depend upon the issue of \"foreseeability.\" Was the clinician able to \"reasonably foresee\" that the medical issues would significantly impair the patient's ability to drive safely [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/53\">",
"     53",
"    </a>",
"    ]?",
"   </p>",
"   <p>",
"    Six states (California, Delaware, Nevada, New Jersey, Oregon, and Pennsylvania) have mandatory reporting requirements regarding potentially unsafe drivers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/54\">",
"     54",
"    </a>",
"    ]. California, for example, requires physicians to report drivers with dementia to the local health department, who then reports them to the Department of Motor Vehicles. In many states the reporter's name is confidential. However, reporting the older adult to the state is uncomfortable for many clinicians who consider it a breach of confidentiality and a threat to the clinician-patient relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13088559\">",
"    <span class=\"h2\">",
"     Canada",
"    </span>",
"    &nbsp;&mdash;&nbsp;A policy in Ontario, Canada requires that physicians report patients who are &ldquo;suffering from a condition that may make it dangerous for the person to operate a motor vehicle&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/55\">",
"     55",
"    </a>",
"    ]. Physicians are offered a small monetary incentive to report unfit patients. In a study of the impact of reporting, approximately one-half of the 59,000 patients reported one year after the incentive was introduced were older than age 60; road crashes resulting in emergency department visits for reported at-risk drivers decreased by 45 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/56\">",
"     56",
"    </a>",
"    ]. However, medical warnings were also associated with an increase in emergency visits for depression and with a decrease in return visits with the reporting physician. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1411?source=see_link\">",
"       \"Patient information: Time to stop driving? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older drivers can be evaluated in the primary care setting. In addition to the past and present medical history, other relevant areas of the history include medications, the use of alcohol and other substances, social support, and driving experience. In the physical examination, assessment of mobility, vision, hearing, and cognitive functioning can provide important clues to driving safety.",
"   </p>",
"   <p>",
"    The American Medical Association (AMA) offers a specific online publication to guide assessment of the older driver [",
"    <a class=\"abstract\" href=\"UTD.htm?3/19/3385/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the clinician has concerns, the most useful approach is to talk with the older patient and family to discuss the evaluation and the clinician's recommendations. There are resources in the community for driving refresher courses and on-the-road evaluation that can supplement the primary care evaluation and provide support if the older driver is not able to recognize their limitations. The primary care evaluation, the conference with the older patient and family, and the clinician's recommendations should be clearly described in the medical record.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     US Census Bureau. State and Country QuickFacts.  file://quickfacts.census.gov/qfd/states/00000.html (Accessed on November 08, 2010).",
"    </li>",
"    <li>",
"     National Institute on Aging.  www.nia.nih.gov/ResearchInformation/ConferencesAndMeetings/WorkshopReport/Figure4.htm (Accessed on November 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/3\">",
"      Betz ME, Lowenstein SR. Driving patterns of older adults: results from the Second Injury Control and Risk Survey. J Am Geriatr Soc 2010; 58:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/4\">",
"      Freund B. Office-based evaluation of the older driver. J Am Geriatr Soc 2006; 54:1943.",
"     </a>",
"    </li>",
"    <li>",
"     California State Senate Proceedings Website. Available at: www.leginfo.ca.gov/ (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/6\">",
"      Fain MJ. Should older drivers have to prove that they are able to drive? Arch Intern Med 2003; 163:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/7\">",
"      Fitten LJ. Driver screening for older adults. Arch Intern Med 2003; 163:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/8\">",
"      Molnar FJ, Patel A, Marshall SC, et al. Clinical utility of office-based cognitive predictors of fitness to drive in persons with dementia: A systematic review. J Am Geriatr Soc 2006; 54:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/9\">",
"      Carr DB, Ott BR. The older adult driver with cognitive impairment: \"It's a very frustrating life\". JAMA 2010; 303:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/10\">",
"      Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/11\">",
"      Jang RW, Man-Son-Hing M, Molnar FJ, et al. Family physicians' attitudes and practices regarding assessments of medical fitness to drive in older persons. J Gen Intern Med 2007; 22:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/12\">",
"      Sims RV, Owsley C, Allman RM, et al. A preliminary assessment of the medical and functional factors associated with vehicle crashes by older adults. J Am Geriatr Soc 1998; 46:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/13\">",
"      Koepsell TD, Wolf ME, McCloskey L, et al. Medical conditions and motor vehicle collision injuries in older adults. J Am Geriatr Soc 1994; 42:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/14\">",
"      Ball K, Owsley C, Sloane ME, et al. Visual attention problems as a predictor of vehicle crashes in older drivers. Invest Ophthalmol Vis Sci 1993; 34:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/15\">",
"      Odenheimer GL, Beaudet M, Jette AM, et al. Performance-based driving evaluation of the elderly driver: safety, reliability, and validity. J Gerontol 1994; 49:M153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/16\">",
"      Marottoli RA, Richardson ED, Stowe MH, et al. Development of a test battery to identify older drivers at risk for self-reported adverse driving events. J Am Geriatr Soc 1998; 46:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/17\">",
"      Sims RV, McGwin G Jr, Allman RM, et al. Exploratory study of incident vehicle crashes among older drivers. J Gerontol A Biol Sci Med Sci 2000; 55:M22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/18\">",
"      Fitten LJ, Perryman KM, Wilkinson CJ, et al. Alzheimer and vascular dementias and driving. A prospective road and laboratory study. JAMA 1995; 273:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/19\">",
"      Gallo JJ, Rebok GW, Lesikar SE. The driving habits of adults aged 60 years and older. J Am Geriatr Soc 1999; 47:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/20\">",
"      Foley DJ, Wallace RB, Eberhard J. Risk factors for motor vehicle crashes among older drivers in a rural community. J Am Geriatr Soc 1995; 43:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/21\">",
"      Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/22\">",
"      Ball KK, Roenker DL, Wadley VG, et al. Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc 2006; 54:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/23\">",
"      . Maintaining lane position with peripheral vision during in-vehicle tasks. Hum Factors 1996; 38:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/24\">",
"      Rizzo M. Impaired driving from medical conditions: a 70-year-old man trying to decide if he should continue driving. JAMA 2011; 305:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/25\">",
"      Retchin SM, Anapolle J. An overview of the older driver. Clin Geriatr Med 1993; 9:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/26\">",
"      Health Care Financing Administration Office of National Cost Estimates. National health expenditures 1988; Health Care Financing. Rev 11: 1:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/27\">",
"      Meuleners LB, Duke J, Lee AH, et al. Psychoactive medications and crash involvement requiring hospitalization for older drivers: a population-based study. J Am Geriatr Soc 2011; 59:1575.",
"     </a>",
"    </li>",
"    <li>",
"     Abrams W, Beers M, Berkow R. Older drivers. In: Merck Manual of Geriatrics, 2nd ed, Whitehouse Station, NJ 1995. p.1420.",
"    </li>",
"    <li>",
"     Warshaw G, Moqeeth S. Hearing Impairment. In: Practical Ambulatory Geriatrics, Yoshikawa TT, Cobbs EL, Brummel-Smith K (Eds), Mosby, St. Louis 1998. p.118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/30\">",
"      Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the \"get-up and go\" test. Arch Phys Med Rehabil 1986; 67:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/31\">",
"      Podsiadlo D, Richardson S. The timed \"Up &amp; Go\": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/32\">",
"      Weiner DK, Duncan PW, Chandler J, Studenski SA. Functional reach: a marker of physical frailty. J Am Geriatr Soc 1992; 40:203.",
"     </a>",
"    </li>",
"    <li>",
"     Flowers CW Jr, Baker RS. Eye Disorders. In: Practical Ambulatory Geriatrics, Yoshikawa TT, Cobbs EL, Brummel-Smith K (Eds), Mosby, St. Louis 1998. p.482.",
"    </li>",
"    <li>",
"     Warshaw, G, Moqeeth, S. Hearing Impairment. In: Practical Ambulatory Geriatrics, Yoshikawa TT, Cobbs EL, Brummel-Smith K (Eds), Mosby, St. Louis 1998. p.118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/35\">",
"      Mulrow CD, Lichtenstein MJ. Screening for hearing impairment in the elderly: rationale and strategy. J Gen Intern Med 1991; 6:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/36\">",
"      Valcour VG, Masaki KH, Blanchette PL. Self-reported driving, cognitive status, and physician awareness of cognitive impairment. J Am Geriatr Soc 2002; 50:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/37\">",
"      Man-Son-Hing M, Marshall SC, Molnar FJ, Wilson KG. Systematic review of driving risk and the efficacy of compensatory strategies in persons with dementia. J Am Geriatr Soc 2007; 55:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/38\">",
"      Ott BR, Heindel WC, Papandonatos GD, et al. A longitudinal study of drivers with Alzheimer disease. Neurology 2008; 70:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/39\">",
"      Ball K, Edwards JD, Ross LA, McGwin G Jr. Cognitive training decreases motor vehicle collision involvement of older drivers. J Am Geriatr Soc 2010; 58:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/40\">",
"      Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/41\">",
"      Stutts JC, Stewart JR, Martell C. Cognitive test performance and crash risk in an older driver population. Accid Anal Prev 1998; 30:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/42\">",
"      Freund B, Gravenstein S, Ferris R, et al. Drawing clocks and driving cars. J Gen Intern Med 2005; 20:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/43\">",
"      Marottoli RA, Cooney LM Jr, Wagner R, et al. Predictors of automobile crashes and moving violations among elderly drivers. Ann Intern Med 1994; 121:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/44\">",
"      Hunt L, Morris JC, Edwards D, Wilson BS. Driving performance in persons with mild senile dementia of the Alzheimer type. J Am Geriatr Soc 1993; 41:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/45\">",
"      Trobe JD, Waller PF, Cook-Flannagan CA, et al. Crashes and violations among drivers with Alzheimer disease. Arch Neurol 1996; 53:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/46\">",
"      Rapoport MJ, Herrmann N, Molnar FJ, et al. Sharing the responsibility for assessing the risk of the driver with dementia. CMAJ 2007; 177:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/47\">",
"      Hunt LA, Murphy CF, Carr D, et al. Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Arch Neurol 1997; 54:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/48\">",
"      Cushman LA, Stein K, Duffy CJ. Detecting navigational deficits in cognitive aging and Alzheimer disease using virtual reality. Neurology 2008; 71:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/49\">",
"      Wood JM, Anstey KJ, Kerr GK, et al. A multidomain approach for predicting older driver safety under in-traffic road conditions. J Am Geriatr Soc 2008; 56:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/50\">",
"      Friedland RP. Strategies for driving cessation in Alzheimer Disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/51\">",
"      Grabowski DC, Campbell CM, Morrisey MA. Elderly licensure laws and motor vehicle fatalities. JAMA 2004; 291:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/52\">",
"      Cable G, Reisner M, Gerges S, Thirumavalavan V. Knowledge, attitudes, and practices of geriatricians regarding patients with dementia who are potentially dangerous automobile drivers: a national survey. J Am Geriatr Soc 2000; 48:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/53\">",
"      Scherlis E. Are physicians liable for injuries caused by impaired patients. Medical Malpractice 1996; VIII:3.",
"     </a>",
"    </li>",
"    <li>",
"     Marottoli R. The assessment of older drivers. In: Principles of Geriatric Medicine and Gerontology, 4th ed, Hazzard WR, Blass JP, Halter JB, Ouslander JG (Eds), McGraw-Hill, New York 1999.",
"    </li>",
"    <li>",
"     Highway traffic act, 1990. Section c.H.8, s. 203 [1]. Government of Ontario.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/19/3385/abstract/56\">",
"      Redelmeier DA, Yarnell CJ, Thiruchelvam D, Tibshirani RJ. Physicians' warnings for unfit drivers and the risk of trauma from road crashes. N Engl J Med 2012; 367:1228.",
"     </a>",
"    </li>",
"    <li>",
"     Physician's Guide to Assessing and Counseling Older Drivers. Available at: www.ama-assn.org/ama/pub/category/10791.html (Accessed on October 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3005 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3385=[""].join("\n");
var outline_f3_19_3385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AGE RELATED CHANGES AND DRIVING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATING OLDER DRIVERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pertinent medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Medications, alcohol, and other substances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Social history, including driving",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mobility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cognitive function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Multimodal evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FAMILY AND CLINICIAN RESOURCES ABOUT OLDER DRIVERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      US STATE LICENSE RENEWAL REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LEGAL ISSUES IN EVALUATING OLDER DRIVERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13088552\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13088559\">",
"      Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3005|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/60/23502\" title=\"figure 1\">",
"      Adjusted MMSE norms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/32/14859\" title=\"table 1\">",
"      Driving restrictions after an event",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/63/30715\" title=\"table 2\">",
"      Assessment of older drivers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/0/2\" title=\"table 3\">",
"      Clinical dementia rating",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1411?source=related_link\">",
"      Patient information: Time to stop driving? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_19_3386="Upper extremity arm pressures";
var content_f3_19_3386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Upper extremity arm pressures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 553px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arm blood pressures are unequal with the left radial artery pressure 35 mmHg lower than the right. The left radial wrist-brachial index is abnormal, consistent with left upper extremity occlusive disease.",
"    <br/>",
"    The arterial waveforms in the right and left subclavian, axillary, and brachial arteries are normal. The right radial artery waveform is normal, but the right ulnar artery waveform is monophasic indicating abnormal flow. The left radial artery waveform is also monophasic, and the waveform in the left ulnar artery is flat indicating no flow. Together with the unequal arm pressures, these waveforms indicate left forearm arterial occlusive disease.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strandness's Duplex Scanning in Vascular Disorders, 4th Edition, Zierler E (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3386=[""].join("\n");
var outline_f3_19_3386=null;
var title_f3_19_3387="Skin disorders associated with celiac disease";
var content_f3_19_3387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Skin disorders associated with celiac disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acquired ichthyosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis herpetiformis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eczema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidermal necrolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nodular prurigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pityriasis rubra pilara",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pustular dermatitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3387=[""].join("\n");
var outline_f3_19_3387=null;
var title_f3_19_3388="Fecal leukocyte testing";
var content_f3_19_3388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Value of fecal leukoctye examination in distinguishing viral gastroenteritis from other causes of acute gastroenteritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viruses",
"       </td>",
"       <td>",
"        PMN, if any",
"       </td>",
"       <td>",
"        0 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Vibrio cholerae",
"        </em>",
"        , EHEC, ETEC, EPEC,",
"        <em>",
"         Giardia lamblia",
"        </em>",
"       </td>",
"       <td>",
"        PMN, if any",
"       </td>",
"       <td>",
"        0 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Shigella",
"        </em>",
"        ,",
"        <em>",
"         Salmonella",
"        </em>",
"        (not typhi),",
"        <em>",
"         Campylobacter jejuni",
"        </em>",
"        ,",
"        <em>",
"         Clostridium difficile",
"        </em>",
"       </td>",
"       <td>",
"        PMN",
"       </td>",
"       <td>",
"        90 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Yersinia enterocolitica",
"        </em>",
"        ,",
"        <em>",
"         Vibrio parahaemolyticus",
"        </em>",
"       </td>",
"       <td>",
"        PMN",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Salmonella typhi",
"        </em>",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoebic dysentery",
"       </td>",
"       <td>",
"        MN",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"       <td>",
"        EO",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PMN: polymorphonuclear leukocytes; EHEC:&nbsp;enterohemorrhagic",
"     <em>",
"      Escherichia coli",
"     </em>",
"     ; ETEC: enterotoxigenic",
"     <em>",
"      E. coli",
"     </em>",
"     ; EPEC: enteropathogenic",
"     <em>",
"      E. coli",
"     </em>",
"     ; MN: mononuclear leukocytes; EO: eosinophilic leukocytes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3388=[""].join("\n");
var outline_f3_19_3388=null;
var title_f3_19_3389="Americans with Disabilities Act";
var content_f3_19_3389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Americans with Disabilities Act",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Title I of the",
"        <strong>",
"         Americans with Disabilities Act of 1990",
"        </strong>",
"        , which took effect July 26, 1992,",
"prohibits private employers, state and local governments, employment",
"agencies, and labor unions from discriminating against qualified",
"individuals with disabilities in job application procedures; hiring;",
"firing; advancement; compensation; job training; and other terms,",
"conditions and privileges of employment. An individual with a",
"disability is a person who:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        Has a physical or mental impairment that substantially limits one or more major life activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Has a record of such an impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Is regarded as having such an impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A qualified employee or applicant with a disability is an",
"individual who, with or without reasonable accommodation, can perform",
"the essential functions of the job in question. Reasonable",
"accommodation may include, but is not limited to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        Making existing facilities used by employees readily accessible to and usable by persons with disabilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Job restructuring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Modifying work schedules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reassignment to a vacant position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acquiring or modifying equipment or devices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adjusting modifying examinations, training materials, or policies, and providing qualified readers or interpreters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        An employer is required to make an accommodation",
"to the known disability of a qualified applicant or employee if it",
"would not impose an \"undue hardship\" on the operation of the employer's",
"business. Undue hardship is defined as an action requiring significant",
"difficulty or expense when considered in light of factors such as an",
"employer's size, financial resources, and the nature and structure of",
"its operation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An employer is not required to lower quality or production",
"standards to make an accommodation, nor is an employer obligated to",
"provide personal use items such as glasses or hearing aids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medical examinations and inquiries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Employers may not ask job applicants about the existence, nature, or",
"severity of a disability. Applicants may be asked about their ability",
"to perform specific job functions. A job offer may be conditioned on",
"the results of a medical examination, but only if the examination is",
"required for all entering employees in similar jobs. Medical",
"examinations of employees must be job related and consistent with the",
"employer's business needs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug and alcohol abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Employees and applicants currently engaging in the illegal use of drugs",
"are not covered by the ADA when an employer acts on the basis of such",
"use. Tests for illegal drugs are not subject to the ADA's restrictions",
"on medical examinations. Employers may hold illegal drug users and",
"alcoholics to the same performance standards as other employees.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        EEOC enforcement of the ADA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The U.S. Equal Employment Opportunity Commission issued regulations to",
"enforce the provisions of Title I of the ADA on July 26, 1991. The",
"provisions originally took effect on July 26, 1992, and covered",
"employers with 25 or more employees. On July 26, 1994, the threshold",
"dropped to include employers with 15 or more employees.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3389=[""].join("\n");
var outline_f3_19_3389=null;
var title_f3_19_3390="Brachial artery puncture";
var content_f3_19_3390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brachial artery puncture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Technique of brachial artery puncture. The brachial artery is palpable in the antecubital fossa just medial to the biceps tendon. The needle should enter the brachial artery just above the antecubital crease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3390=[""].join("\n");
var outline_f3_19_3390=null;
var title_f3_19_3391="Gram stain urine 1 with answer";
var content_f3_19_3391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram-negative rods in urine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of unspun urine (x1000) shows an inflammatory cell and numerous Gram-negative bacilli. Escherichia coli grew from this specimen. The presence of one or more bacteria per oil immersion field of fresh unspun urine usually indicates infection with 100,000 or more organisms per mL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_19_3391=[""].join("\n");
var outline_f3_19_3391=null;
